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1. Introduction 
 
1.1. Impaired glucose metabolism: a global issue 
 
 The body’s inability to control its blood glucose levels adequately can be 
described as impaired glucose metabolism and, if certain criteria are fulfilled, as diabetes 
mellitus. This kind of metabolic disorder is becoming more and more prevalent in today’s 
world; thus, placing a huge burden onto our economic and healthcare systems.  
On a global level, Ogurtsova et al estimated that in 2015, 415 million people worldwide 
between the ages 20-79 years had diabetes and that the global health costs due to diabetes 
were 673 billion US (United States) dollars (Ogurtsova et al. 2017). Another study found 
that in 2015, the global expenditure for diabetes was about 1.31 trillion US dollars 
including indirect costs (Bommer et al. 2017).  
A study from the US comparing data sets from 1988-1994 and 2011-2012 with regards 
to diabetes prevalence found an increase over time with a prevalence between 12-14% in 
2011-2012 (Menke et al. 2015). Data from another US-based study conducted in 2016-
2017 showed a prevalence of diagnosed diabetes of 9.7%. This study also revealed that 
type 2 diabetes is predominant in comparison to type 1 diabetes (Xu et al. 2018).  
Data for Germany show that while the prevalence of diabetes did not vary significantly 
between 1997-1999 and 2008-2011, there was an increase in diagnosed diabetes seen 
(Heidemann et al. 2016). Tamayo et al found that the diabetes prevalence was 9.9% in 
2010 upon age and gender standardization (Tamayo et al. 2016). A study investigating 
the prevalence of gestational diabetes (pregnancy-related diabetes) in Germany between 
2014-2015 found a prevalence of 13.2% (Melchior et al. 2017). Regional differences 
within Germany have been detected with regards to impaired glucose metabolism (Stöckl 
et al. 2016). 
An increase in the prevalence of diabetes and the associated healthcare costs is expected 
in the future. Globally, it is expected that about 642 million people will be affected by 
diabetes in 2040 which will certainly have an impact on the social and financial systems 
(Ogurtsova et al. 2017). 
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 In the following, the state of impaired glucose metabolism and diabetes will be 
defined and classified, signs and symptoms will be discussed, complications will be 
outlined and diagnostic options given. 
 
 
1.1.1. Definition and types of prediabetes and diabetes mellitus 
 
Impaired glucose metabolism and diabetes mellitus (in the latter referred to as 
diabetes) are characterized by a malfunctioning control of blood glucose levels due to 
varying conditions. Today, we differentiate between diabetes, impaired glucose tolerance 
(IGT) and impaired fasting glucose (IFG). The World Health Organization (WHO) 
defines diabetes as fasting plasma glucose ≥7.0 mmol/l (126 mg/dl) or 2-hour plasma 
glucose after administration of an oral glucose tolerance test (OGTT) consisting of 75g 
oral glucose, ≥ 11.1 mmol/l (200 mg/dl). IGT is defined as fasting plasma glucose <7.0 
mmol/l (126 mg/dl) and 2-hour plasma glucose ≥7.8 and <11.1 mmol/l (140-200 mg/dl). 
IFG is defined as fasting plasma glucose between 6.1 and 6.9 mmol/l (110-125 mg/dl) 
and 2-hour plasma glucose <7.8 mmol/l (140 mg/dl) (World Health Organization and 
International Diabetes Federation 2006). The American Diabetes Association (ADA) 
Expert Committee lowered the levels for defining IFG from 6.1 mmol/l (110 mg/dl) to 
5.6 mmol/l (100 mg/dl) in 2003 (Genuth et al. 2003). IGT and IFG can be summarized as 
prediabetes. Normal glucose tolerance is characterized as the absence of either 
prediabetes or diabetes. 
 
Pathological changes in the blood glucose metabolism can have different underlying 
conditions. According to the ADA, there are four subgroups (American Diabetes 
Association 2018):  
The first subgroup is called type 1 diabetes and is considered an autoimmune 
condition. Autoantibodies against insulin, islet cells, glutamic acid decarboxylase (GAD) 
and tyrosinphosphatases destroy the pancreatic insulin-producing β-cells, thus leading to 
an absolute deficiency of insulin (American Diabetes Association 2014). Type 1 diabetes 
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can occur in conjunction with other autoimmune and also genetic disorders (Kota et al. 
2012) and reveals itself mostly during childhood. An upward trend in incidence has been 
reported (Patterson et al. 2009). A special subgroup is called idiopathic type 1 diabetes 
which is characterized by impaired production of insulin without signs for autoimmune 
processes (American Diabetes Association 2010). In a study published in 2018, the 
prevalence of type 1 diabetes in adults in the US was 0.5% and amongst adults diagnosed 
with diabetes, type 1 diabetes was the underlying subgroup in 5.6% (Xu et al. 2018). 
Type 2 diabetes is nowadays the predominant form of diagnosed diabetes (Xu et al. 
2018). The condition can be described as insulin-resistance of the target tissues in 
combination with a relative insulin deficiency (American Diabetes Association 2014). 
Type 2 diabetes is commonly seen in combination with other components of the metabolic 
syndrome such as impaired lipid metabolism, elevated blood pressure and obesity (Lin et 
al. 2015).  
The term prediabetes encompasses IGT and/or IFG and represents the precursor stage of 
diabetes. More than one out of three adults in the US suffer from prediabetes (Menke et 
al. 2015) and it is a credible and often underestimated disease state, with an approximate 
74.0% lifetime risk of progressing to diabetes (Ligthart et al. 2016). Wu et al showed that 
progression from newly diagnosed prediabetes to type 2 diabetes was 30.3% in 3 years 
(Wu et al. 2017).  
Gestational diabetes (pregnancy-related diabetes) is difficult to distinguish from 
preexisting type 1 or type 2 diabetes. Currently, gestational diabetes is defined as a first-
time diagnosis of diabetes in the second or third trimester without signs for pre-existing 
diabetes (American Diabetes Association 2018).  
 
Other etiologies include genetic defects in insulin production as well as action, 
endocrine conditions, disorders of the exocrine pancreas system, diabetes related to 
contact with chemicals or intake of drugs, infections and less common forms of immune-
mediated diabetes that can also lead to impaired glucose metabolism (American Diabetes 
Association 2014, American Diabetes Association 2018). 
12 
1.1.2. Symptoms of impaired glucose metabolism 
 
 There are no specific symptoms indicating prediabetes status. It has been found 
that patients with prediabetes did not show reduction in health-related quality of life in 
comparison to subjects with newly diagnosed diabetes (Seppälä et al. 2013).  
 In subjects affected by diabetes, symptoms can develop in hyperglycemia (high 
blood glucose levels) or hypoglycemia (low blood glucose levels) and can range from 
subtle to life-threatening. Typical hyperglycemic symptoms are polyuria (increased 
urination) and polydipsia (increased thirst) but also unspecific symptoms such as weight-
loss or polyphagia (increased appetite) (American Diabetes Association 2014). A life-
threatening complication of uncontrolled diabetes is called ketoacidosis. This condition 
is more often seen in type 1 diabetes and presents with high blood glucose levels, 
metabolic acidosis, and elevated ketone levels. The typical presentation of ketoacidosis 
includes symptoms such as polyuria, polydipsia, weight loss, fatigue, dyspnea, and 
vomiting as reviewed by Westerberg in 2013 (Westerberg 2013). On the other side, 
hypoglycemia can also be life-threatening and can present with autonomous, 
neuroglycopenic as well as malaise symptoms (Deary et al. 1993). 
 
 
1.1.3. Complications and comorbidities 
 
  Due to the development of advanced glycation end-products (AGE) in the 
bloodstream affecting vessel walls, impaired glucose metabolism can lead to micro- and 
macrovascular changes; thus, contributing to the global vascular risk. This metabolic 
disorder predominantly affects the cardiovascular, renal, and nervous system as well as 
the retina (Fowler 2008). Microvascular and macrovascular disease in type 2 diabetes are 
both independently associated with an adverse cardiovascular outcome. The combination 
of both carries the highest risk (Mohammedi et al. 2017). Interestingly, many of the 
complications associated with impaired glucose metabolism are statistically similar in 
subjects with prediabetes as compared to type 2 diabetes (Farrell and Moran 2014). 
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Furthermore, diabetes and its complications pose a substantial economic burden on 
healthcare systems worldwide. A study published in 2002 showed that the costs of 
complications in type 2 diabetes were calculated to an estimate of 47,240 US dollar per 
patient over a time span of 30 years with macrovascular disease being responsible for the 
majority of the total cost over the first 5 years (Caro et al. 2002). Multiple chronic 
comorbidities are often seen with the leading cluster consisting of high blood pressure, 
hyperlipidemia and adiposity (Lin et al. 2015). Subsequently, the rate of complications 
increases over time (Grimaldi et al. 2000).  
 
 
Microvascular complications 
 
 Chronic kidney disease in diabetes, also known as diabetic nephropathy, is seen 
in about 20-40% of all diabetics (American Diabetes Association 2007). In a prospective 
cohort study conducted in Singapore by Low et al, 45% of subjects with type 2 diabetes 
developed chronic kidney disease with albuminuria as the most common first 
manifestation (Low et al. 2016). Hypertension has been found to be an independent risk 
factor for diabetic nephropathy (Bentata et al. 2015).  
 Diabetic retinopathy (damage of the retina due to diabetes) affected 
approximately 93 million people worldwide in 2010 and its main features of retinal 
neovascularization and macular edema are potentially vision-threatening (Yau et al. 
2012). Today, we discriminate the proliferative and the non-proliferative subtypes. Polyol 
accumulation, AGE, oxidative damage, proteinkinase C and growth factors have all been 
described as contributing factors, as extensively reviewed by Fong et al (Fong et al. 
2004). Risk factors for diabetic retinopathy are elevated blood glucose and blood pressure 
as well as dyslipidemia (Yau et al. 2012).  
 The term diabetic neuropathy describes nerve damage due to diabetes and 
summarizes entities such as diabetic mononeuropathy, peripheral neuropathy and 
autonomic neuropathy. Its detailed pathophysiology is unknown; however, oxidative 
stress, polyol accumulation and AGE are considered to play a role (Fowler 2008). 
According to the ADA, reduction in the perception of vibration as well as loss of pressure 
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sensation as assessed by a 10g monofilament can be seen as predictors for the 
development of foot ulcers (American Diabetes Association 2007). Risk factors for 
peripheral diabetic neuropathy include, besides others, uncontrolled blood glucose levels 
as well as body height and age (Adler et al. 1997).  
 
 
Macrovascular complications 
 
 Macrovascular complications such as coronary artery disease (CAD), peripheral 
arterial disease or cerebrovascular disease and stroke are mostly due to processes leading 
to atherosclerosis (Fowler 2008). Diabetes is associated with a two to threefold risk of 
atherosclerotic diseases and affects women more strongly than men (Kannel and McGee 
1979). Data indicate that diabetes has deteriorating effects on the cardiac function as well 
(Devereux et al. 2000).  
 
 
Comorbidities 
 
 Elderly patients with diabetes show an increased risk for dementia (Xu et al. 
2004). Also, subjects with type 2 diabetes appear to have a higher prevalence of 
depression (Ali et al. 2006). It has, however, also been discussed that depressive 
symptoms may lead to a higher risk of type 2 diabetes in women (Arroyo et al. 2004). 
Also, a higher risk of hip fractures is suggested in patients with diabetes and potential 
explanations have been extensively reviewed by Starup-Linde et al (Starup-Linde et al. 
2017). Additionally, subjects with impaired glucose metabolism are more prone to 
infections, e.g. post-surgery (Chen et al. 2009).  
 As described earlier, type 2 diabetes is often associated with comorbidity clusters 
which include obesity (Lin et al. 2015). Fat distribution plays an important role since 
visceral adipose tissue (VAT) seems to have a stronger negative effect on cardiometabolic 
risk markers than subcutaneous adipose tissue (SAT) (Liu et al. 2010). Interestingly, 
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abdominal superficial subcutaneous adipose tissue seems to have advantageous effects in 
subjects with diabetes (Golan et al. 2012). Additionally, it has been shown that the relation 
of VAT to SAT, the so-called VAT/SAT ratio, can predict cardiovascular disease in 
subjects with diabetes (Fukuda et al. 2018). In elderly women, abdominal obesity as 
defined by employing the waist-to-hip ratio has emerged as a risk factor for the 
development of diabetes (Kaye et al. 1991). VAT has been shown to be responsible for 
disturbances in the lipid-lipoprotein profiles in women with impaired glucose tolerance 
(Lemieux et al. 2011).  
 
 
1.1.4. Diagnostics 
 
 Blood glucose levels should ideally be measured in venous blood plasma samples, 
as soon as the sample is drawn. Besides measurement of fasting glucose levels, a 75g 
OGTT may be administered on patients with suspected impaired glucose metabolism 
(World Health Organization and International Diabetes Federation 2006, American 
Diabetes Association 2014). Testing of glycosylated haemoglobin A1 (HbA1c), 
reflecting average blood glucose levels of the last 2 to 3 months, has been described as 
acceptable by the ADA in their 2018 Standards of Care, but a standardized and certified 
method is recommended (American Diabetes Association 2018). Subjects at risk for 
diabetes should undergo screening for diabetes and prediabetes (American Diabetes 
Association 2018). 
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1.2. The fat compartments surrounding the heart 
 
 Adipocytes are cells that primarily store energy-equivalents in the form of 
triglycerides. Clusters of adipocytes are called adipose tissue which can naturally be 
found in multiple locations in the body. Excess body fat is being stored in so-called 
ectopic fat depots. While some of these fat depots interact more locally with other 
surrounding cells and organs, others have systemic effects (Britton and Fox 2011). 
Examples for ectopic fat depots include VAT, pericardial fat, or hepatic fat (Britton and 
Fox 2011). 
There is scientific evidence that ectopic fat depots, specifically VAT and epicardial fat 
are associated with cardiometabolic disease (Fox et al. 2007, Mahabadi et al. 2009).  
 
 In the following, the anatomy, physiology and pathophysiology of the fat depots 
surrounding the heart will be reviewed with a special emphasis on epicardial fat. 
 
 
1.2.1. Anatomy and description of the pericardial fat depots  
 
The heart is surrounded by different fat compartments. Pericardial fat can be seen 
as an umbrella term for the two distinct fat compartments epicardial and paracardial 
fat (Bertaso et al. 2013, Sacks and Fain 2007). Existing literature is highly inconsistent 
in the nomenclature of the fat compartment anatomy. Figure 1 outlines the localization of 
the different fat compartments as they will be referred to in the following study. 
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Figure 1: The pericardial fat depots  
Magnetic Resonance (MR) image of the thorax in the axial orientation. The heart is shown 
in the long axis. Epicardial fat (white asterisks) and paracardial fat (orange dotted lines) 
are separated by the pericardium (white arrow). The sum of epi- and paracardial fat is 
referred to as pericardial fat. Abbreviations: A, anterior; Ao, aorta descendens; L, left; 
LV, left ventricle; P, posterior; R, right; RV, right ventricle; V, vertebra. 
 
Epicardial fat is the fat compartment in closest proximity to the myocardium, 
within the visceral pericardium (Bertaso et al. 2013). Epicardial fat and the myocardium 
are in close proximity without a separating fascia and both are supplied by the same 
coronary artery blood supply (Corradi et al. 2004). It should be pointed out that epicardial 
adipocytes are smaller in volume (Marchington et al. 1989) and size (Bambace et al. 
2011) as compared to other fat depots. Epicardial fat contains cardiac ganglia (Arora et 
al. 2003) and can be infiltrated by inflammatory cells (Mazurek et al. 2003). It has been 
reported that epicardial fat thickness over the right ventricle is associated with right 
ventricle cavity size (Iacobellis 2009a) and that there is a muscle-fat ratio for each 
ventricle (Corradi et al. 2004). 
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The term paracardial fat is used to describe the fat compartment more distant 
from the heart and located outside the parietal pericardial layer (Bertaso et al. 2013). 
Other terms found in the literature that refer to paracardial fat are ‘mediastinal fat’ (Chen 
et al. 2015) or ‘intrathoracic fat’ (Thanassoulis et al. 2010a).  
 
 
1.2.2. Physiology and pathophysiology 
 
There are numerous physiological functions attributed to the epicardial fat depot. 
However, many functions are still not fully understood. 
Epicardial fat has been shown to have an insulin-independent high uptake of fatty 
acids, as well as an insulin-stimulated high rate of lipogenesis (Marchington and Pond 
1990). Based on these findings, it was hypothesized that the epicardial fat layer might 
serve in a buffer function to the myocardium by protecting it from high levels of free fatty 
acids while also supplying energy equivalents (Marchington and Pond 1990, Marchington 
et al. 1989). Notably, the epicardial fat depot does not decrease as fast as other body fat 
depots during exercise or weight loss surgery in type 2 diabetes (Jonker et al. 2013, van 
Schinkel et al. 2014). The expression of the mitochondrial uncoupling protein 1 is 
increased in epicardial fat, and it has thus been suggested that epicardial fat may also have 
a protective function against hypothermia (Sacks et al. 2009). Moreover, it is now known 
that epicardial fat has an endocrine function. Epicardial fat expresses and secretes over 
100 cytokines (Swifka et al. 2008). In samples collected during elective coronary artery 
bypass grafting, interleukin-1β, interleukin-6, tumor-necrosis-factor and other cytokines 
have been detected (Mazurek et al. 2003). Paracrine, which is close communication of 
cells by chemical substances, as well as vasocrine signaling pathways have been 
discussed for the interaction with the myocardium, the vessels and epicardial fat with its 
different cellular components (Sacks and Fain 2007, Yudkin et al. 2005).  
Although displaying many beneficial features, epicardial fat has also been reported to 
play a role in multiple pathological processes. Firstly, data suggest that epicardial fat is 
associated with coronary artery disease (CAD) (Iacobellis et al. 2011). In a large study 
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comprising 3,367 subjects without a history of CAD, epicardial fat was associated with 
progressing coronary artery calcification (Mahabadi et al. 2014). In a post-mortem study 
validated by autopsies, there was an association seen between epicardial fat volume and 
the extent of coronary stenosis (Sequeira et al. 2015). Notably, epicardial fat volume may 
also help to identify subjects at risk for coronary artery calcium burden (Yerramasu et al. 
2012). Interestingly, epicardial fat also seems to play a role in myocardial relaxation 
(Vural et al. 2014, Dabbah et al. 2014) and has been reported to be increased in patients 
who suffered from myocardial infarction (Homsi et al. 2018).  
Moreover, epicardial fat has an impact on the electrophysiology of the heart and may play 
a role in atrial fibrillation. Iacobellis et al noted, that epicardial fat thickness, as assessed 
by echocardiography, was higher in subjects suffering from permanent, rather than 
paroxysmal atrial fibrillation (Iacobellis et al. 2014c). In the Framingham Heart Study, an 
independent association of epicardial fat with prevalent atrial fibrillation was detected 
(Thanassoulis et al. 2010b). It has to be pointed out that the Framingham Heart Study 
uses the word “pericardial fat” to describe the fat inside the pericardial sac which for this 
study is defined as “epicardial fat”. Additionally, epicardial fat seems to possess the 
ability to induce fibrotic changes of the myocardium (Venteclef et al. 2015). 
Chronic obstructive pulmonary disease (COPD) can affect the heart as well. It has been 
shown that subjects suffering from COPD with advanced right ventricular systolic 
dysfunction had decreased epicardial fat thickness (Kaplan et al. 2015). Also, epicardial 
fat thickness is reported to be adversely associated with severity of COPD itself (Kiraz et 
al. 2016).  
Epicardial fat seems to play a very important role in impaired glucose metabolism such 
as prediabetes and diabetes and these interactions will be discussed in a separate chapter 
of the introduction. 
 
The physiological role of paracardial fat is not fully understood as of today. Only 
a few studies have investigated this particular fat compartment and found a correlation 
with visceral adipose tissue and metabolic risk factors (Thanassoulis et al. 2010a, Sicari 
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et al. 2011). A correlation between paracardial fat and coronary artery stenosis has been 
reported, but not as strongly as for epicardial fat (Sequeira et al. 2015).  
Six months exercise decreased paracardial fat volume, as reported by Jonker et al, but not 
epicardial fat in type 2 diabetics (Jonker et al. 2013). Bariatric surgery clearly reduced the 
amount of paracardial fat to a greater extent than epicardial fat (van Schinkel et al. 2014, 
Wu et al. 2016). 
 
 
1.2.3. Clinical relevance of epicardial fat 
 
 As described earlier, epicardial fat possesses a magnitude of beneficial but also 
several potentially adverse features. The full clinical relevance of epicardial fat is not 
fully understood as of today. Epicardial fat is discussed to be associated with CAD 
including non-calcified plaques (Alexopoulos et al. 2010), atrial fibrillation (Thanassoulis 
et al. 2010b), and it correlates with MR-derived signs for myocardial dysfunction in obese 
subjects with type 2 diabetes (Evin et al. 2016). It is increased in impaired glucose 
metabolism (Arpaci et al. 2015). Epicardial fat seems to influence established 
cardiometabolic risk factors such as hypertension (Teijeira-Fernandez et al. 2008), and 
glucose levels (Iacobellis et al. 2008a). In a combined positron emission tomography 
(PET) and computed tomography (CT) study, performed by Janik et al, epicardial fat 
measured on CT images was found to better predict ischemia than the established 
coronary artery calcium scoring test (Janik et al. 2010). Imaging of the epicardial fat 
compartment is easily performed by various imaging techniques as reviewed by 
Davidovich et al (Davidovich et al. 2013). Despite its relevance, assessment of epicardial 
fat volume or thickness is so far not routinely practiced in the general work-up of subjects 
at risk for cardiometabolic diseases. 
Epicardial fat can also be the primary origin of thoracic pain in case of epicardial fat 
necrosis (Baig et al. 2012).  
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1.2.4. The role of epicardial fat in obesity and impaired glucose 
metabolism 
 
Impaired glucose metabolism is, along with central obesity, disturbances in lipid 
metabolism and hypertension, a feature of the metabolic syndrome. This symptom 
complex is attributed to the Western lifestyle as shown by Rodriguez-Monforte et al 
(Rodriguez-Monforte et al. 2017). It has become clear that it is rather VAT that is 
associated with the development of impaired glucose metabolism (Neeland et al. 2012). 
VAT correlates well with epicardial fat as described by Iacobellis et al in 2003. They 
stated that epicardial fat assessed by echocardiography can be suggested as a predictor 
for VAT (Iacobellis et al. 2003). This correlation may be particularly true for obese 
subjects with diabetes (Jain et al. 2015, Levelt et al. 2016). Moreover, epicardial fat 
thickness has also been suggested as an indicator for obesity (Song et al. 2015). Vasques 
et al used ultrasound to measure the sagittal abdominal diameter and found that epicardial 
adipose tissue could be estimated by employing this parameter (Vasques et al. 2013).  
Moreover, epicardial fat thickness by ultrasound seems to predict hepatic steatosis in 
obesity (Iacobellis et al. 2014a). 
 
Little is known about the interactions of epicardial fat and the early stages of impaired 
glucose metabolism. Arpaci et al found transthoracic echocardiographically assessed 
epicardial fat thickness to be elevated in prediabetes as compared to subjects with normal 
glucose tolerance (Arpaci et al. 2015). Also, epicardial fat has been discussed as a marker 
for cardiovascular disease risk in subjects with prediabetes (Altin et al. 2016). Insulin 
resistance has been shown to be an independent predictor of epicardial fat thickness (Altin 
et al. 2017). This finding has also been described in coronary artery disease (Baldasseroni 
et al. 2013). Interestingly, Iacobellis and Leonetti were able to show that epicardial fat 
assessed by echocardiography was associated with insulin-resistance due to obesity 
(Iacobellis and Leonetti 2005). Components of the metabolic syndrome are also 
associated with epicardial fat (Wang et al. 2009).  
Epicardial fat has been shown to be elevated in subjects with type 2 diabetes (Song et 
al. 2015, Cetin et al. 2013, Wang et al. 2009). In a cross-sectional study conducted in 
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Korea, Chun et al found that an increased epicardial fat thickness has an impact on the 
diabetes prevalence in males (Chun et al. 2015). Moreover, in subjects with diabetes, 
epicardial fat displayed a more proinflammatory profile than in healthy controls and 
adipocytes were found to be larger than in the control group (Bambace et al. 2014). 
Additionally, miRNA expressed by epicardial fat, seems to play a role in coronary artery 
disease in subjects with type 2 diabetes (Liu et al. 2016). 
 
Briefly, it should be pointed out that higher amounts of epicardial fat were also 
reported in type 1 diabetics as compared to healthy controls (Iacobellis et al. 2014b).  
 
 
1.2.5. Imaging of the pericardial fat depots 
 
The pericardial fat depots can be assessed by different imaging techniques 
including ultrasound, computed tomography (CT) and magnetic resonance imaging 
(MRI), although there is currently no single gold-standard (Davidovich et al. 2013). Non-
radiological analysis like autopsy studies have also been performed and contributed to a 
better understanding of the fat depots (Sequeira et al. 2015).  
 
Echocardiography is an easily accessible, cost-effective tool for the assessment 
of pericardial fat depots. Normally, epicardial fat can be assessed in parasternal long-axis 
and short-axis views; clinical applications have further been reviewed by Iacobellis and 
Willens (Iacobellis and Willens 2009b). Potentially hazardous epicardial fat thickness 
threshold values have also been evaluated by Iacobellis et al (Iacobellis et al. 2008b). 
Agreements between echocardiographically assessed epicardial fat and epicardial fat 
from MRI are good (Iacobellis et al. 2003). However, echocardiography is limited in 
adipose patients and is a very subjective imaging technique that highly depends on the 
operator.  
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Computed tomography (CT) has been widely used to assess pericardial fat 
depots. This modality has been shown to be feasible (Sarin et al. 2008) and highly 
reproducible in the volumetric assessment of epicardial fat (Gorter et al. 2008). The 
assessment of the different pericardial fat compartments is dependent on the 
identifiability of the thin pericardium. The administration of contrast agent is, however, 
not necessary for this distinction (Cheng et al. 2010). Today, computer-assisted 
assessment promises reliable and fast measurement of cardiac fat depots (Ding et al. 
2015). CT has been applied for the assessment of pericardial fat depots in large studies 
such as the Framingham Heart Study (Rosito et al. 2008, Thanassoulis et al. 2010a, 
Thanassoulis et al. 2010b) or the Heinz Nixdorf Recall study (Mahabadi et al. 2014). 
However, the employment of CT is always linked to radiation exposure of the mostly 
healthy study subjects. 
 
Cardiac magnetic resonance (CMR) imaging has also been employed for the 
assessment of pericardial fat depots. MRI provides a high soft tissue contrast and 
therefore plays a very important role in fat imaging. It has for example been employed in 
research concerning whole-body adipose tissue profiles (Machann et al. 2005). MRI – in 
comparison to CT – does not require ionizing radiation. MRI-based exams as well as CT 
tend to be more operator-independent than echocardiography (Wang et al. 2003). 
Volumetric (Flüchter et al. 2007) as well as thickness measurements (Iacobellis et al. 
2003) have been conducted so far; however, study results indicate that the volumetric 
approach has a better interobserver variability (Flüchter et al. 2007). Pericardial fat 
volume assessment by MRI has been validated against postmortem studies in merino 
sheep, thereby establishing MRI is an important diagnostic tool (Nelson et al. 2009). 
Images can be acquired in four-chamber view orientation (Jonker et al. 2013) or in the 
short axis (Chen et al. 2015). It has been shown that MRI-based cardiac fat mass as 
assessed in a volumetric approach on short axis views correlates very well with 
planimetric assessment of cardiac fat derived from long axis images (Sironi et al. 2012). 
Studies on scanners with 3 Tesla magnets have also been conducted in the last years 
(Gaborit et al. 2012).  
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Analysis of the fatty acid composition of different fat depots including epicardial 
fat has been conducted by proton nuclear MR spectroscopy (Burgeiro et al. 2016). 
Epicardial fat has also been assessed in PET/CT and its relationship to myocardial 
ischemia was analyzed (Janik et al. 2010). 
 
  
25 
1.3. Aim and scientific hypothesis 
 
Subjects with impaired glucose metabolism and diabetes are at considerable risk for 
developing cardiovascular disease (Kannel and Mcgee 1979). However, the underlying 
detailed pathophysiology is highly complex. It is also known that certain body fat depots 
such as VAT play a role in impaired glucose metabolism and metabolic alterations 
(Lemieux et al. 2011, Hayashi et al. 2003, Fox et al. 2007). The ectopic fat depot 
epicardial fat has recently emerged as a potential correlate for cardiovascular risk (Rosito 
et al. 2008). Earlier cohort studies often employed radiation-based CT (Mahabadi et al. 
2009, Mahabadi et al. 2014). Due to its high soft-tissue contrast and non-ionizing image 
generation, MRI is suitable for large cohort studies. Also, assessment of epicardial fat has 
been described as feasible in MRI (Flüchter et al. 2007). It is clear that the trend in 
imaging cohort studies including thousands of healthy subjects is shifting towards MRI 
(Gatidis et al. 2017) and that there will be an increasing need to analyze body structures 
on these images. Future applications for assessment of the pericardial fat compartments 
could include not only epidemiological research but also approaches in individualized 
medicine.  
 
The aim of the underlying study was to manually assess the pericardial fat depots on 
MR images in the cine steady state free precession (SSFP) sequence, long axis (four 
chamber view), in a clinically cardiovascular healthy cohort. We aimed at comparing 
measurements from the systolic and diastolic assessment. Epicardial and paracardial fat 
depots were then analyzed in the light of impaired glucose metabolism as well as in 
relation to other MRI-derived body fat depot measurements and traditional cardiovascular 
risk factors. We also aimed at analyzing the association between epi-and paracardial fat 
and imaging-based LV parameters for subclinical LV dysfunction. Parts of this study aim 
have been previously published (Rado et al. 2019). 
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Our hypothesis was that assessing pericardial fat depots on MR images in the cine 
SSFP sequence is feasible for assessing the pericardial fat depots in both the systolic and 
diastolic heart cycle. We hypothesized that there are differences in epi- and paracardial 
fat between subjects with normal glucose tolerance and subjects with prediabetes and 
diabetes that allow for a more detailed characterization of their role in impaired glucose 
metabolism. Also, we hypothesized that there are independent associations between MR-
based markers for early LV impairment and epicardial fat. 
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2. Material and Methods 
 
2.1. Study population 
 
The KORA study – short for “Kooperative Gesundheitsforschung in der Region 
Augsburg” (Cooperative Health Research in the Region Augsburg) - is a follow-up of the 
MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg 
surveys that were conducted by the WHO in the 1980s and 1990s in the Augsburg region 
(Löwel et al. 2005). The KORA study was initiated in 1996 as a follow-up 
epidemiological study with a focus on cardiovascular risk and metabolic diseases. The 
detailed study set up has been described by Holle et al (Holle et al. 2005). The history 
and structure of the KORA study is depicted in Figure 2. 
 
Figure 2: Overview of the KORA study 
This figure shows an overview of the KORA study including the MRI study (depicted as 
‘MRT’) which is nested within the KORA FF4 cohort, a follow up of the original S4 
cohort. Abbreviations: GEFU, General (Morbidity) Follow Up; MRT, Magnetic 
Resonance Tomography; Tel, Telephone interview; U, Untersuchung (examination). This 
image is a courtesy of KORA Studien Koordination, Institut für Epidemiologie II, 
Helmholtz Zentrum München, Germany. 
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 The KORA MRI sub-study is nested within the KORA FF4 cohort and subjects 
were recruited between 2013/2014. Female and male subjects aged 25-74 years were 
included. The study details regarding inclusion and exclusion criteria for the MRI sub-
study have been outlined in a previous publication (Bamberg et al. 2017). In brief, 
subjects were eligible for participation if they had an established glucose tolerance status 
(either previously diagnosed diabetes or results of an OGTT). Exclusion criteria included 
age greater 72 years, history of clinically significant cardiovascular disease, inability to 
undergo MRI exams (e.g. implants, claustrophobia), pregnancy or lactation, or missing 
OGTT results. Moreover, subjects with contraindications for undergoing contrast-
enhanced MRI exams were also excluded from the study (e.g. renal impairment with 
serum creatinine ≥1.3mg/dl, allergies to gadolinium-based contrast). Before participating 
in the MRI examination, informed written consent was obtained from each study subject. 
Ethical approval was also collected from the institutional review board of the Medical 
Faculty of the Ludwig Maximilians University Munich, Germany (Bamberg et al. 2017, 
Rado et al. 2019) under the project number 498-12. This ethical approval was reviewed 
and confirmed by the institutional review board of the Medical Faculty of the Eberhard 
Karls University Tübingen, Germany under the project number 576/2016BO2. 
 
Subjects without an established diagnosis of diabetes underwent an OGTT. 
Glucose tolerance status was determined according to WHO recommendations: diabetes 
was defined as fasting plasma glucose ≥7.0 mmol/l (126 mg/dl) or 2-hour plasma glucose 
≥11.1 mmol/l (200 mg/dl). IGT was defined as fasting plasma glucose <7.0 mmol/l (126 
mg/dl) and 2-hour plasma glucose ≥7.8 and <11.1mmol/l (140-200mg/dl). IFG was 
defined as fasting plasma glucose 6.1 to 6.9 mmol/l (110 to 125 mg/dl) and 2-hour plasma 
glucose <7.8 mmol/l (140 mg/dl) (World Health Organization and International Diabetes 
Federation 2006).  
 
 Further health-related information, including physical exams, blood samples and 
interviews, was performed at dedicated study centers in an established and standardized 
fashion between 2013 and 2014 (Bamberg et al. 2017). Collection of relevant covariables 
will be described later. 
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2.2. MR imaging parameters 
 
The complete study protocol for the KORA MRI study including the imaging 
parameters for the different sequences has been described in the study overview 
(Bamberg et al. 2017). In brief, the KORA MRI study focuses on cardiovascular imaging 
as well as assessment of different body fat compartments. Subjects included in this study 
underwent whole-body MRI with a pre-set protocol including multiple imaging 
sequences. Image acquisition was performed using a 3 Tesla Magnetom Skyra MRI 
(Siemens Healthineers, Erlangen, Germany) (Bamberg et al. 2017).  
 
For the single-slice analysis of the pericardial fat depots, a cine steady-state free 
precession (SSFP) sequence in the long axis of the heart (four chamber view) was 
employed with the imaging parameters as follows: time-to-repetition (TR) 29.97 ms, 
time-to-echo (TE) 1.46 ms, field-of-view (FOV) 297 x 360 mm, slice thickness 8 mm, 
matrix 240 x 160, spatial resolution 1.5 x 1.5 mm2, flip angle 63° (Bamberg et al. 2017). 
 
The volumetric analysis of pericardial fat, VAT and SAT was conducted in a dual-
echo volume interpolated breath hold examination (VIBE) Dixon sequence with the 
following imaging parameters: TR 4.06 ms, TE 1.26, 2.49 ms, FOV 488 x 716 mm, slice 
thickness 1.7 mm, matrix 256 x 256, spatial resolution 1.7 x 1.7 mm2, flip angle 9° 
(Bamberg et al. 2017). 
 
Further cardiac imaging included a short-axis cine SSFP sequence with the 
following imaging parameters: TR 29.97 ms, TE 1.46 ms (10sl), FOV 297 x 360 mm, 
slice thickness 8 mm, matrix 240 x 160, spatial resolution 1.5 x 1.5 mm2, flip angle 62°, 
as well as a Fast Low Angle Shot (FLASH) sequence with the following parameters: TR 
700-1000 ms, TE 1.55 ms, TI (inversion time) 280-345 ms, FOV 300 x 360, slice 
thickness 8 mm, matrix 256 x 140, spatial resolution 1.4 x 1.4 mm2, flip angle 20-55° 
(Bamberg et al. 2017). 
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The proton-density fat fraction of the liver (PDFFhepatic) was assessed in a multi-
echo VIBE Dixon sequence during a 15 second breath hold with imaging parameters as 
follows: TR 8.90 ms, TE 1.23, 2.46, 3.69, 4.92, 6.15, 7.38 ms, FOV 393 x 450 mm, slice 
thickness 4 mm, matrix 256 x 179, spatial resolution 1.8 x 1.8 mm2, flip angle 4 ° 
(Bamberg et al. 2017).  
 
 
2.3. MR image analysis 
 
Pericardial fat depots (single-slice approach): Image analysis was conducted 
employing a software (OsiriX Lite, Pixmeo SARL, Bernex, Switzerland). The MR 
images were manually imported into the software. For measurements of the fat areas, the 
tool called ‘polygonal region of interest (ROI)’ was employed. The pericardium was 
individually identified. Epicardial fat was segmented manually between the myocardium 
and the pericardium while small structures embedded in the adipose tissue (e.g. the 
coronary arteries) were not segmented separately. The pericardial fat compartment was 
segmented following the anatomical borders of the myocardium, lungs, aorta and ventral 
thoracic wall. Small structures embedded in the adipose tissue were also not segmented 
separately. Epi- and pericardial fat areas were assessed in the maximal systolic and 
diastolic heart cycle which were individually identified (Rado et al. 2019) (Figure 3).  
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Figure 3: Assessment of the epicardial and pericardial fat compartments 
Manual assessment of the pericardial (blue line) and the epicardial (green line) fat depots 
in the systolic (A) and the diastolic (B) heart cycle on images derived from the cine SSFP 
sequence in the long axis (four chamber view). The amount of paracardial fat was 
calculated by subtraction following segmentation (Rado et al. 2019). Abbreviations: Ao, 
aorta descendens; L, left; LV, left ventricle; R, right; RV, right ventricle; V, vertebra. 
 
The areas of the pericardial and epicardial fat depots were recorded in centimeters squared 
[cm2] and the results were documented in an Excel sheet (Microsoft, Redmond, 
Washington, USA). The amount of paracardial fat was determined by subtraction 
following the formula: paracardial fat = pericardial – epicardial fat (Rado et al. 2019). 
Additionally, image quality was evaluated on a five-point Likert scale with 1 = ‘very 
good’ to 5 = ‘not assessable’. A final consensus reading was performed to rule out gross 
reading mistakes. Additionally, intra- and interreader reproducibility were assessed in a 
cohort subset of N=38. Throughout the reading process, readers were blinded with regards 
to subject identity and health status (Rado et al. 2019).  
 
 Pericardial Fat (volumetric approach): From the acquired dual-echo Dixon 
images, automatically calculated fat-selective tomograms were employed for further 
analysis. MR images were visualized on an offline workstation (SyngoVia, Siemens 
Healthineers, Forchheim, Germany) and axial tomograms were reconstructed 
automatically with a slice thickness of 2.5 mm, seamless. Pericardial fat was segmented 
from the diaphragm to the pulmonary bifurcation by manually selecting the slices. 
Between 28 and 36 slices were included for this analysis, based on the individuals’ 
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anatomical heart sizes. The reconstructed tomograms were exported to a workstation and 
were reworked with an inhouse algorithm (Figure 4). Segmentations were corrected 
manually if necessary. Results are given in milliliters (ml) (J. Machann, personal 
communication).  
 
 
 
Figure 4: Principle of semiautomatic volumetric segmentation of pericardial fat 
This figure shows the fat-selective axial tomograms of one study subject as reconstructed 
from the dual-echo Dixon sequence before (A) and after (B) semiautomatic segmentation 
of pericardial fat (yellow). Figure 4C is a magnification view of the segmented pericardial 
fat on four different levels. This image material is a courtesy of PD Dr Jürgen Machann, 
Section on Experimental Radiology, Department of Diagnostic and Interventional 
Radiology, University Hospital Tübingen, Tübingen, Germany. 
 
VAT/SAT: VAT and SAT were analyzed on the fat-selective tomograms of the 
dual-echo VIBE Dixon sequence. A multiplanar reconstruction of the coronal data set 
into axial tomograms was performed from the femoral heads to the shoulders. The 
volumetric assessment of VAT was conducted between the femoral heads and cardiac 
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apex. The assessment of SAT was conducted between the femoral heads and diaphragm 
(Storz et al. 2018). An inhouse algorithm based on fuzzy-clustering (Würslin et al. 2010) 
was employed to semi-automatically assess VAT and SAT (Figure 5). The segmentation 
was corrected manually if necessary (Storz et al. 2018). Results are displayed in liters.  
 
 
Figure 5: Principle of visceral (VAT) and subcutaneous (SAT) adipose tissue 
assessment  
Fat-selective axial tomograms were reconstructed from coronal MR images (levels 
indicated by white lines on the sagittal and coronal images). VAT (red) and SAT (yellow) 
were automatically segmented. Figure A shows a study subject with a larger, and figure 
B with a smaller amount of VAT. This image material is a courtesy of PD Dr Jürgen 
Machann, Section on Experimental Radiology, Department of Diagnostic and 
Interventional Radiology, University Hospital Tübingen, Tübingen, Germany. 
 
PDFFhepatic: As previously described, a ROI was placed into the hepatic tissue on 
the PDFF maps, thereby carefully avoiding big adjacent vessels (Hetterich et al. 2016). 
Results are displayed in per cent. 
 
LV parameters included late gadolinium enhancement (LGE), LV ejection 
fraction (EF) as well as left ventricular concentricity index (LVCI) which includes 
myocardial mass and end-diastolic volume. Data for EF as well as LVCI were analyzed 
on SSFP images in the short axis (10sl) while LGE data were derived from FLASH short 
axis and a four-chamber view. Image analysis on the short-axis SSFP images was 
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performed in a semiautomated fashion as previously described by employing a software 
(cvi42, Circle Cardiovascular Imaging, Calgary, Canada) (Bamberg et al. 2017, Rado et 
al. 2019, Schlett et al. 2018). An EF of <55% was considered pathological (Ueda et al. 
2015). The LVCI was derived from LV myocardial mass divided by LV end-diastolic 
volume (Pun et al. 2011). LVCI values greater than 1.3 g/ml were considered pathological 
(Gaasch and Zile 2011). LGE was analyzed subendocardially, midmyocardially and 
epicardially by two readers in a consensus (Bamberg et al. 2017). The presence of LGE 
was considered pathological (Wu et al. 2001). A composite endpoint of subclinical LV 
impairment was defined for further analysis and consisted of the presence of LGE and/or 
LVEF <55% and/or LVCI > 1.3 g/ml (Rado et al. 2019). 
 
 
2.4. Covariables 
 
 Covariables were collected from standardized interviews, laboratory work and 
physical exams. The collection of the covariables has been previously described (Holle 
et al. 2005, Bamberg et al. 2017). 
 
 Body mass index (BMI) as anthropometric measure was calculated as weight by 
height squared [kg/m2]. With regards to blood pressure, hypertension was diagnosed if 
systolic blood pressures were ≥ 140mmHg and diastolic blood pressures ≥ 90mmHg. 
Also, hypertension was defined as taking antihypertensives whilst being aware of the 
hypertension diagnosis. Medication considered antihypertensive included beta blockers, 
diuretics etc. according to recent recommendations. Antithrombotic medication 
comprised antiplatelet and anticoagulant medication. The intake of drugs such as statins 
and fibrates were considered as lipid-lowering medication. Alcohol consumption data 
were derived from interviews and are given in g/day. Smoking information was derived 
from standardized interviews and results were grouped in the categories never, ex- and 
current smoker (Bamberg et al. 2017). Laboratory parameters such as total cholesterol, 
high-density lipoprotein (HDL), low-density lipoprotein (LDL), or triglycerides were 
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derived from fasting blood samples and were assessed in a standardized fashion as 
described by Seissler et al (Seissler et al. 2012). 
 
 
2.5. Statistical analysis 
 
Intraclass correlation coefficients (ICC) were calculated for analysis of intrareader 
and interreader reproducibility. The correlation between the single-slice and volumetric 
approach to assess pericardial fat was calculated by Pearson’s pairwise correlation 
coefficient.  
Demographic, clinical and imaging-based data are shown for all included study 
subjects as well as for the subgroups ‘normal glucose tolerance’, ‘prediabetes’ and 
‘diabetes’ and are shown as either median [25th;75th percentile] for continuous data or 
number (percentage) for categorical data and differences amongst these subgroups were 
analyzed either by Kruskal-Wallis equality of population rank test for continuous data, 
and χ2-test or Fisher’s exact test for categorical data (Rado et al. 2019). 
Pericardial fat depots in the systolic and diastolic measurements were described 
by giving the minimum, maximum and quartiles including the median. Additionally, the 
median [25th;75th percentile] is given for the different pericardial fat depots in both systole 
and diastole for the female and male subgroups separately. 
Correlations between cardiac fat data derived from systole and diastole were 
calculated by Pearson’s pairwise correlation coefficient and are presented as scatterplots. 
Agreements between systolic and diastolic cardiac fat parameters were also evaluated by 
plotting relative differences in Bland-Altman-Plots.  
Data for the pericardial fat depots for all study subjects included as well as the 
subgroups ‘normal glucose tolerance’, ‘prediabetes’ and ‘diabetes’ are presented as 
median [25th; 75th percentile] and p-values were analyzed by Kruskal-Wallis equality of 
population rank test. This analysis was conducted for the systolic and diastolic data. 
Additionally, boxplots depict the differences in systolic epicardial/paracardial fat between 
the subgroups (Rado et al. 2019). 
36 
Stepwise adjustment for potential confounders of the association between 
prediabetes and diabetes to epicardial/paracardial fat was performed by employing 
median regression analysis and data including β-coefficients, 95% confidence intervals 
and p-values are presented in a table format. Data were firstly adjusted for age and gender 
only, followed by adjustment for traditional cardiovascular risk factors (CVRF) which 
included hypertension, smoking, LDL and triglycerides. Additional adjustment included 
measures of body fat, namely BMI, SAT and VAT (Rado et al. 2019). A multivariate 
analysis of the relationship of epicardial/paracardial fat to cardiovascular risk factors was 
performed by employing median regression and data are presented in a table format 
including β-coefficients, 95% confidence intervals and p-values (Rado et al. 2019).  
Boxplots depict the differences in epicardial/paracardial fat amounts between 
healthy subjects and subjects showing subclinical LV impairment (Rado et al. 2019). The 
relationship between epicardial/paracardial fat and LV impairment was analyzed in a 
median regression model and was stepwise adjusted for traditional cardiovascular risk 
factors including diabetes status and VAT (Rado et al. 2019). 
Median regression models were employed since data for epicardial and 
paracardial fat were not evenly distributed (Rado et al. 2019).  
P-values <0.05 were defined as statistically significant. Data were analyzed in 
Stata 14.1 (Stata Corporation, College Station, TX, U.S.A.) (Rado et al. 2019). 
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3. Results 
 
3.1. General results 
 
400 subjects were primarily enrolled in the KORA MRI study. Images with an 
image quality rated 1-4 were included. Subjects with an image quality rated “5” (not 
assessable) and subjects without available images were not included in the final analysis 
(28 subjects, 7%, respectively). Of these, 1% had incomplete acquisition of the cine SSFP 
sequence and 6% had insufficient image quality due to motion artifacts, FOV 
misalignment, incomplete data acquisition or inability to delineate the pericardium 
sufficiently. Thus, 372 subjects were included in the underlying analysis (93%) (Rado et 
al. 2019). 
 
 
3.2. Quality management 
 
We found higher intraclass correlation coefficients (ICC) for intrareader than for 
interreader reproducibility. Results are depicted in Table 1. In general, ICCIntrareader as well 
as ICCInterreader were higher for the systolic as compared to the diastolic measurements. 
Due to this finding, further statistical analyses were conducted with the systolic fat 
measurements (Rado et al. 2019) unless otherwise indicated. 
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Table 1: Intraclass correlation coefficients for intrareader and interreader 
reproducibility of epicardial and pericardial fat depots 
This table depicts the intraclass correlation coefficients for intra- as well as interreader 
reproducibility for the epicardial and pericardial fat depots in both systole and diastole. 
These data have previously been published (Rado et al. 2019). 
 
Intraclass correlation coefficients (ICC) Systole Diastole 
ICCIntrareader (epicardial fat) 0.918 0.844 
ICCIntrareader (pericardial fat) 0.985 0.979 
ICCInterreader (epicardial fat) 0.884 0.765 
ICCInterreader (pericardial fat) 0.927 0.888 
 
 
There was a strong positive correlation seen between the systolic as well as 
diastolic single-slice pericardial fat measurement with the volumetric approach with a 
correlation coefficient of r=0.74, p<0.001.  
  
 
3.3. Study population characteristics  
 
Demographic data and clinical characteristics of the underlying study population 
are displayed in Table 2. Of 372 subjects included in the final analysis, 220 subjects had 
normal glucose tolerance, 100 were prediabetics and 52 were diabetics (Rado et al. 2019). 
All diabetic subjects included in this final analysis had type 2 diabetes (Rado et al. 2019). 
The median age in all subjects included was 57 years [49;64] and increased significantly 
from healthy controls to prediabetics and diabetics (p<0.001). Overall, 59.4% of the 
subjects included were male and the percentage of males increased from controls to the 
prediabetes and diabetes group (53.2%, 64% and 76.9%; p=0.004, respectively) (Rado et 
al. 2019). 
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With regards to cardiovascular risk factors, there was a significant increase from 
subjects with normal glucose tolerance to prediabetics and diabetics concerning BMI 
(26.6 kg/m2 vs 29.4 kg/m2 vs 30.4 kg/m2; p<0.001), hypertension (22.3% vs 45% vs 
71.2%; p<0.001), and triglycerides (95.5 mg/dl vs 136.5 mg/dl vs 177.82 mg/dl; 
p<0.001). Additionally, prediabetics and diabetics had lower HDL levels as compared to 
subjects with normal glucose tolerance (p<0.001). However, no significant differences 
were found for LDL and smoking (p=0.09 and p=0.11, respectively) (Rado et al. 2019).  
With regards to body fat composition, subjects with prediabetes and diabetes had 
higher amounts of VAT, SAT and PDFFhepatic as compared to subjects with normal 
glucose tolerance (all p<0.001) (Rado et al. 2019).  
In comparison to normoglycemic controls, intake of antihypertensive and lipid-
lowering medication was higher in the prediabetic and diabetic group (both p<0.001) 
(Rado et al. 2019).  
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Table 2: Demographic and clinical characteristics of the included study subjects 
Data are presented for the total study population as well as for the subgroups ‘normal glucose tolerance’, ‘prediabetes’ and ‘diabetes’. 
Absolute numbers (percentage) are given for categorical data and the median (25th; 75th percentile) is given for continuous data. 
Abbreviations: “BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PDFF, proton density fat fraction; 
SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue” (Rado et al. 2019). This table has previously been published in the British 
Journal of Radiology (Rado et al. 2019). 
 
 
All subjects 
Normal glucose  
tolerance 
Prediabetes Diabetes 
p-value 
 
N=372 N=220 N=100 N=52 
Age (years) 57 (49;64) 53 (47;62) 59 (51;66) 63.5 (58;69.5) <0.001 
Male gender (%) 221 (59.4%) 117 (53.2%) 64 (64%) 40 (76.9%) 0.004 
BMI (kg/m2) 27.99 (25.16; 31) 26.58 (24.25; 29.01) 29.43 (27.3; 33.82) 30.43 (27.12; 33.09) <0.001 
Hypertension (%) 131 (35.2%) 49 (22.3%) 45 (45%) 37 (71.2%) <0.001 
Antihypertensive 
medication (%) 
97 (26.1%) 39 (17.7%) 32 (32%) 26 (50%) <0.001 
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Antithrombotic 
medication (%) 
8 (2.2%) 3 (1.4%) 4 (4%) 1 (1.9%) 0.32 
HDL (mg/dl) 59.52 (48; 72) 62 (51; 77) 59.26 (49.72; 69.6) 48.16 (40.5; 61.2) <0.001 
LDL (mg/dl) 138 (116; 161) 136 (115.5; 162.5) 143.5 (123; 161.5) 130.5 (109.5; 150.5) 0.09 
Triglycerides (mg/dl) 110.5 (77.28; 162.5) 95.5 (69.5; 129.69) 136.5 (98; 184.62) 177.82 (114.76; 273.09) <0.001 
Lipid 
lowering  
medication (%) 
42 (11.3%) 15 (6.8%) 9 (9%) 18 (34.6%) <0.001 
SAT (l) 7.41 (5.53; 10.05) 6.75 (5.16; 8.88) 8.65 (6.35; 11.97) 8.65 (6.3; 11.27) <0.001 
VAT (l) 4.23 (2.69; 6.35) 3.14 (1.8; 4.72) 5.44 (3.97; 7.32) 6.88 (5.76; 8.45) <0.001 
PDFFhepatic (%) 4.77 (2.79; 12.21) 3.44 (2.2; 5.9) 11.6 (4.79; 17.93) 15.89 (6.86; 24.13) <0.001 
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Smoking status      
0.11 
   Never-smoker  136 (36.6%) 88 (40.0%) 32 (32.0%) 16 (30.8%) 
   Ex-smoker  163 (43.8%) 84 (38.2%) 50 (50.0%) 29 (55.8%) 
   Current-smoker 73 (19.6%) 48 (21.8%) 18 (18.0%) 7 (13.5%) 
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MRI-derived data for LV-function parameters were available in 345 subjects; 208 of them 
had normal glucose tolerance, 93 were prediabetics and 44 were diabetics. Significant 
changes between the groups with different glucose tolerance status were seen for EF, 
myocardial mass, LV end-diastolic volume, and LVCI but not for LGE.  Of the 345 
subjects included in this sub-analysis, 93 had at least one of the components of the defined 
composite endpoint for subclinical LV impairment (27%, respectively) with 6 (1.7%) 
subjects showing more than one of these findings (Rado et al. 2019). There was an 
increase in the composite pathologic LV findings seen from healthy subjects to 
prediabetics and diabetics (16.8%, 35.5%, 56.8%, p<0.001; respectively) (Rado et al. 
2019). Further details are shown in Table 3. 
 
 
Table 3: Differences in early LV impairment as determined by MR image analysis 
between subjects with normal glucose tolerance, prediabetics and diabetics  
Data are presented for all subjects included as well as for the subgroups ‘normal glucose 
tolerance’, ‘prediabetes’, and ‘diabetes’. Numbers (percentage) are shown for categorical 
data and median (25th;75th percentile) for continuous data. Abbreviations: “EF, ejection 
fraction; LGE, late gadolinium enhancement; LV, left ventricular; LVCI, left ventricular 
concentricity index” (Rado et al. 2019). This table has previously been published in the 
British Journal of Radiology (Rado et al. 2019). 
 
  
All  
subjects  
  
Normal  
glucose  
tolerance 
Pre- 
diabetes 
Diabetes 
p-value 
 N=345 N=208 N=93 N=44 
LV EF (%) 
70  
(65;75) 
70  
(65;74) 
72  
(66;77) 
69  
(64;74) 
0.03 
 LV EF <55%  
14  
(4.1%) 
10  
(4.8%) 
0  
(0%) 
4  
(9.1%) 
0.01 
LV myocardial 
mass (g) 
141 
(115;166) 
127 
(106;160) 
151 
(131;172) 
148 
(133;170) 
<0.001 
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LV end-diastolic 
volume (ml/m2) 
66  
(56;75) 
69  
(61;80) 
60  
(52;68) 
55  
(48;63) 
<0.001 
LVCI (g/ml) 
1.06 
(0.9;1.28) 
0.99 
(0.87;1.14) 
1.22 
(1.02;1.35) 
1.30 
(1.05;1.57) 
<0.001 
LVCI >1.3 g/ml  
77  
(22.3%) 
26 
(12.5%) 
30  
(32.3%) 
21 
(47.7%) 
<0.001 
LGE 
8  
(2.3%) 
2  
(1%) 
4  
(4.3%) 
2  
(4.6%) 
0.06 
LGE or LVCI 
>1.3 g/ml or LV 
EF <55%  
93  
(27%) 
35 
(16.8%) 
33  
(35.5%) 
25 
(56.8%) 
<0.001 
 
 
3.4. Pericardial fat depots in systolic and diastolic assessment 
 
Within the 372 subjects assessed, systolic pericardial fat values ranged from 3.3 
cm2 to 98.1 cm2 with a median of 26.5 cm2 and diastolic pericardial fat values ranged 
from 3.3 cm2 to 83.0 cm2 with a median of 23.6 cm2.  With regards to epicardial fat 
assessment, systolic epicardial fat values ranged from 0 cm2 to 33.7 cm2 with a median of 
8.7 cm2, and diastolic epicardial fat values ranged from 0 cm2 to 32.1 cm2 with a median 
of 7.7 cm2. The calculated paracardial fat amount ranged from 1.3 cm2 to 66.4 cm2 with 
a median of 18.3 cm2 in the systole, and from 1.6 cm2 to 64.1 cm2 with a median of 16.0 
cm2 in the diastole. Table 4 summarizes the above data. The median amounts of systolic 
epicardial and paracardial fat have been previously published (Rado et al. 2019). 
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Table 4: Pericardial fat depots in systolic and diastolic assessment 
All 372 subjects were included. This table shows the minimum, 25th, 50th, 75th percentile 
as well as the maximum amount of epi-, para- and pericardial fat in the systolic and 
diastolic measurements. All numbers given are in centimeters squared (cm2). 
Abbreviations: p, percentile 
 
 
minimum p25 p50 p75 maximum 
Pericardial fat  
(systole) 3.3 18.4 26.5 40.3 98.1 
Pericardial fat  
(diastole) 3.3 15.9 23.6 35.8 83.0 
Epicardial fat  
(systole) 0 5.6 8.7 11.2 33.7 
Epicardial fat  
(diastole) 0 5.1 7.7 10.6 32.1 
Paracardial fat  
(systole) 1.3 11.1 18.3 27.3 66.4 
Paracardial fat  
(diastole) 1.6 9.7 16.0 25.4 64.1 
  
 
 Correlations between the systolic and diastolic data for pericardial, epicardial as 
well as paracardial fat were investigated and very strong correlations were found between 
the systolic and diastolic data for all fat depots with the highest correlation coefficient for 
pericardial fat (r=0.99 vs r=0.98 vs r=0.90, for pericardial, paracardial and epicardial fat, 
respectively; Figure 6). 
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Figure 6: Correlations between the different pericardial fat depots in the systolic 
and diastolic heart cycle 
This figure shows the correlations between the systolic (y-axis) and diastolic data (x-axis) 
for the pericardial (A), epicardial (B) and paracardial (C) fat depots.  
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 Generally, data derived from systolic measurements were higher than from the 
diastolic measurements. In pericardial fat, the mean difference was 10.7%. In epicardial 
fat, the mean difference was 11.3%. For paracardial fat, the mean difference was 10.8%. 
Figure 7 depicts the agreements between systolic and diastolic measurements for the 
pericardial, epicardial and paracardial fat depots. 
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Figure 7: Agreements between systolic and diastolic measurements of the different 
pericardial fat depots 
Agreements between the data sets derived from systolic and diastolic measurements for 
pericardial (A), epicardial (B) and paracardial (C) fat are presented as Bland-Altman 
plots. Relative differences are plotted in per cent on the y-axis and averages are given in 
centimeters squared on the x-axis. 
 
 
In men, who accounted for 221 included subjects (59.4%, respectively), the 
median amount of epicardial fat in the systole was 9.2 cm2 (6.7;12.2) and for women (151 
subjects, 40.5%, respectively) 6.9 cm2 (4.7;9.7). The median amount of epicardial fat in 
the diastole was 8.8 cm2 (6.3;11.6) for men and 6.0 cm2 (4.0;9.1) for women. The median 
amount of pericardial fat in the systole was 32.6 cm2 (23.3;46.2) for men and 19.9 cm2 
(12.9;26.8) for women. The median amount of pericardial fat in the diastole was 30.8 cm2 
(21.5;42.4) for men and 17.1cm2 (11.2;24.5) for women, respectively. For the calculated 
amount of paracardial fat, the median amount of paracardial fat in the systole was 23.1 
cm2 (16.0;33.9) for men and 11.7 cm2 (7.8;17.5) for women, as well as 21.5 cm2 
(14.4;30.9) for men and 10.2 cm2 (6.7;16.0) for women in the diastole. In general, all fat 
depots were larger in men as compared to women, irrespective of the systolic or diastolic 
measurements.  
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In the systole, there was a significant increase in median pericardial fat from 
healthy controls to prediabetics and diabetics (22.8 cm2 vs 30.1 cm2 vs 40.3 cm2; p<0.001, 
respectively). Similar trends were seen for both the epicardial and paracardial fat depot 
separately (7.7 cm2 vs 9.2 cm2 vs 10.3 cm2 and 14.3 cm2 vs 20.3 cm2 vs 27.4 cm2; both 
p<0.001, respectively) (Rado et al. 2019); Table 5 and Figure 8).  
 
 
Table 5: Differences in the pericardial fat depots as assessed in the systole between 
subjects with normal glucose tolerance, prediabetics and diabetics  
Data are shown as median (25th; 75th percentile) and are displayed in centimeters squared 
[cm2]. Data from the table have been partially published (Rado et al. 2019). 
 
 All  
subjects 
 
Normal  
glucose  
tolerance 
Prediabetes 
 
Diabetes 
 
p-value 
 N=372 N=220 N=100 N=52  
Pericardial fat 
[cm2] 
26.5 
(18.4;40.3) 
22.8 
(14.6;32.1) 
30.1 
(22.8;43.5) 
40.3 
(29;53.6) 
<0.001 
Epicardial fat 
[cm2] 
8.7 
(5.6;11.2) 
7.7  
(5;10.3) 
9.2  
(6.9;11.8) 
10.3 
(7.6;14.4) 
<0.001 
Paracardial fat 
[cm2] 
18.3 
(11.1;27.3) 
14.3  
(9;22.5) 
20.3 
(15.5;30.1) 
27.4 
(20.7;37.8) 
<0.001 
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Figure 8: Differences between epicardial and paracardial fat in subjects with normal 
glucose tolerance, prediabetics and diabetics 
Boxplots depicting the stepwise increase in both systolic epicardial (A) and systolic 
paracardial (B) fat from healthy subjects to prediabetics and diabetics. All p were <0.001. 
The fat amounts are presented in centimeter squared [cm2] on the y-axis. This figure has 
previously been published in the British Journal of Radiology (Rado et al. 2019). 
 
 
Similar results were found for the diastolic assessment of the pericardial fat 
depots. Pericardial fat and both the epi- as well as paracardial fat depot increased from 
subjects with normal glucose tolerance to prediabetics and diabetics. Results are shown 
in Table 6. 
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Table 6: Differences in the pericardial fat depots as assessed in the diastole between 
subjects with normal glucose tolerance, prediabetics and diabetics 
Data are shown as median (25th; 75th percentile) and are displayed in centimeters squared 
[cm2].  
 
 All  
subjects 
 
Normal  
glucose  
tolerance 
Prediabetes 
 
Diabetes 
 
p-value 
 N=372 N=220 N=100 N=52  
Pericardial fat 
[cm2] 
23.6 
(15.9;35.8) 
20.0 
(12.8;29.4) 
26.2 
(20.9;39.6) 
38.0 
(24.7;48.4) 
<0.001 
Epicardial fat 
[cm2] 
7.7 
(5.1;10.6) 
6.9  
(4.4;9.7) 
8.6  
(5.9;11.1) 
9.8  
(7.5;13.3) 
<0.001 
Paracardial fat 
[cm2] 
16.0 
(9.7;25.4) 
12.4 
(7.7;20.6) 
18.7 
(13.6;27.3) 
26.2 
(17.6;34.1) 
<0.001 
 
 
3.5. Adjustment for potential confounders 
 
 In an unadjusted setting, there was an association between epicardial fat and 
prediabetes as well as diabetes seen (both p ≤0.02). After adjusting for age and gender, 
the association to prediabetes became non-significant (p=0.14) whereas epicardial fat was 
still associated with diabetes (p=0.02). The association attenuated for both the prediabetic 
and diabetic group after additionally adjusting for cardiovascular risk factors including 
hypertension, triglycerides, LDL and smoking (p=0.37 and 0.59, respectively) (Rado et 
al. 2019). Details are depicted in Table 7. 
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Table 7: Stepwise adjustment for potential confounders of the association between 
epicardial fat with prediabetes and diabetes 
The systolic data for epicardial fat were employed for this analysis. Data are derived from 
median regression and are displayed as ß-coefficient (95% confidence interval) and p-
value. P-values in bold are statistically significant. Abbreviations: “BMI, body mass 
index; CI, confidence interval; CVRF, cardiovascular risk factor; LDL, low-density 
lipoprotein; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue” (Rado et 
al. 2019). CVRF included hypertension, smoking, LDL and triglycerides. This table has 
previously been published in the British Journal of Radiology (Rado et al. 2019). 
 
 Normal 
glucose 
tolerance 
Prediabetes Diabetes 
Epicardial fat 
 β (95 CI) 
p-
value 
β (95 CI) 
p-
value 
Unadjusted -Ref.- 1.54 
(0.23;2.84) 
0.02 
3.04 
(1.39;4.68) 
<0.001 
Adjusted for      
Age, gender -Ref.- 0.94  
(-0.29;2.16) 
0.14 
1.98 
(0.36;3.61) 
0.02 
Age, gender,  
CVRF 
-Ref.- 0.55  
(-0.66;1.76) 
0.37 
0.47  
(-1.26;2.2) 
0.59 
Age, gender, 
 CVRF, BMI 
-Ref.- 0.3  
(-0.87;1.47) 
0.62 
-0.08  
(-1.71;1.56) 
0.93 
Age, gender,  
CVRF, SAT 
-Ref.- 0.29  
(-0.89;1.47) 
0.63 
0.35  
(-1.3;2.01) 
0.68 
Age, gender,  
CVRF, VAT 
-Ref.- -0.41  
(-1.55;0.73) 
0.48 
-0.92  
(-2.53;0.7) 
0.27 
 
 
 For paracardial fat, there was a significant association between paracardial fat 
and prediabetes as well as diabetes after adjustment for age and gender seen (p=0.01 and 
<0.001, respectively). The association became non-significant for the prediabetes group 
53 
after adjusting for age, gender and cardiovascular risk factors. A significant association 
was seen for the diabetes group after adjustment for age, gender, CVRF without (p=0.04) 
and with BMI (p=0.03), as well as after adjustment for age, gender, CVRF and SAT 
(p=0.048) (Rado et al. 2019). Details are depicted in Table 8. 
 
 
Table 8:  Stepwise adjustment for potential confounders of the association between 
paracardial fat with prediabetes and diabetes 
The systolic data for paracardial fat were employed for this analysis. Data are derived 
from median regression and are displayed as ß-coefficient (95% confidence interval) and 
p-value. P-values in bold are statistically significant. Abbreviations: “BMI, body mass 
index; CI, confidence interval; CVRF, cardiovascular risk factor; LDL, low-density 
lipoprotein; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue” (Rado et 
al. 2019). This table has previously been published in the British Journal of Radiology 
(Rado et al. 2019). 
 Normal 
glucose 
 tolerance 
Prediabetes Diabetes 
Paracardial fat 
 β (95 CI) 
p-
value 
β (95 CI) p-value 
Unadjusted -Ref.- 5.15 
(1.36;8.94) 
0.01 
13.08 
(8.31;17.85) 
<0.001 
Adjusted for      
Age, gender 
 
-Ref.- 4.45 
(1.27;7.63) 
0.01 
8.77 
(4.57;12.97) 
<0.001 
Age, gender,  
CVRF 
-Ref.- 3.59  
(-0.1;7.28) 
0.06 
5.43 
(0.15;10.71) 
0.04 
Age, gender, 
CVRF, BMI 
-Ref.- 1.77  
(-1.34;4.88) 
0.26 
4.89 
(0.54;9.24) 
0.03 
Age, gender,  
CVRF, SAT 
-Ref.- 0.56  
(-2.74;3.86) 
0.74 
4.68 
(0.05;9.31) 
0.048 
Age, gender,  
CVRF, VAT 
-Ref.- -2.16  
(-4.91;0.59) 
0.12 
-1.72  
(-5.6;2.16) 
0.39 
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 In multivariate analysis, most traditional cardiovascular risk factors including age, 
hypertension or LDL were not significantly associated with either epicardial or 
paracardial fat. There was a strong association seen between VAT and epicardial as well 
as VAT and paracardial fat (β: 1.08 [0.76; 1.4], p<0.001; and β: 4.10 [3.32; 4.88], 
p<0.001, respectively). Furthermore, epicardial fat was associated with current smoking 
(β: 1.39 [0.07; 2.70], p=0.04). There was a negative association between paracardial fat 
and SAT seen (p=0.04) (Rado et al. 2019). Further details are given in Table 9.  
 
 
Table 9: Multivariate analysis of the relationship between the epicardial and 
paracardial fat depots to cardiovascular risk factors including body fat depots  
Systolic data for epicardial and paracardial fat were employed. Data are derived from 
median regression and are displayed as β-coefficient (95% confidence interval). 
Significant p-values are marked in bold font. Abbreviations: “CI, confidence interval; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; PDFF, proton-density fat 
fraction; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue” (Rado et al. 
2019). This table has been previously published in the British Journal of Radiology (Rado 
et al. 2019). 
  Epicardial fat Paracardial fat 
  β (95%CI) p-value β (95%CI) p-value 
Age (years) 0.03 (-0.03; 0.09) 0.27 0.01 (-0.14; 0.15) 0.93 
Male gender (%) -0.72 (-2.14; 0.70) 0.32 0.87 (-2.57; 4.31) 0.62 
Hypertension 
(%) 
-0.48 (-1.55; 0.59) 0.38 0.71 (-1.88; 3.31) 0.59 
LDL (mg/dl) -0.01 (-0.03; 0.001) 0.08 0 (-0.04; 0.04) 1.00 
HDL (mg/dl) 0.004 (-0.03; 0.04) 0.81 0.005 (-0.08; 0.09) 0.91 
Triglyceride 
(mg/dl) 
0.002 (-0.005; 0.008) 0.59 -0.002 (-0.02; 0.01) 0.8 
Alcohol (g/day) 0.007 (-0.02; 0.03) 0.54 -0.03 (-0.08; 0.02) 0.29 
Smoking     
   Never-smoker  -Ref.-  -Ref.-  
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3.6. Cardiac fat depots and early left-ventricular impairment 
 
 In general, subjects with early LV impairment as assessed on MR images, had 
significantly higher amounts of both epicardial and paracardial fat as compared to 
healthy subjects (p<0.001) (Rado et al. 2019) (Figure 9). 
Figure 9: Differences between amounts of epicardial and paracardial fat in 
subjects with and without signs for left ventricular impairment  
Epicardial (A) and paracardial (B) fat amounts in relation to signs of LV cardiac 
impairment (endpoint of LVEF<55%; presence of LGE; LVCI >1.3g/ml). Fat amounts 
are presented in centimeters squared [cm2] on the y-axis. This figure has been previously 
published in the British Journal of Radiology (Rado et al. 2019). 
   Ex-smoker  0.8 (-0.23; 1.82) 0.13 -1.27 (-3.76; 1.23) 0.32 
  Current-smoker 1.39 (0.07; 2.70) 0.04 -1.45 (-4.64; 1.73) 0.37 
VAT (l) 1.08 (0.76; 1.4) <0.001 4.10 (3.32; 4.88) <0.001 
SAT (l) -0.02 (-0.19; 0.16) 0.87 -0.46 (-0.89; -0.032) 0.04 
PDFFhepatic (%) -0.04 (-0.11; 0.03) 0.21 -0.17 (-0.33; 0.001) 0.05 
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 In an unadjusted setting, both epicardial and paracardial fat were associated with 
the combined endpoint of LV impairment (p=0.004 and <0.001, respectively). The 
association between epicardial fat and LV impairment persisted after adjustment for 
cardiovascular risk factors including diabetes (β: 1.63 (0.5; 2.76), p= 0.005). The 
association even remained independent upon additional adjustment for VAT (β: 1.13 
(0.22; 2.03), p=0.02) but became non-significant upon adjustment for BMI (p=0.09) 
(Rado et al. 2019). 
For paracardial fat, loss of significance was seen after adjustment for diabetes status 
(p=0.13) (Rado et al. 2019). Further details on the stepwise adjustment are given in Table 
10.  
 
 
Table 10: Epicardial and paracardial fat and associations to signs for early LV 
impairment  
Systolic data were employed for epicardial and paracardial fat and a stepwise adjustment 
for multiple variables was conducted. Data are presented as β-coefficient (95% 
confidence interval) and significant p-values are marked in bold font. Abbreviations: 
“BMI, body mass index; CI, confidence interval; LDL, low-density lipoprotein; LV, left 
ventricular; VAT, visceral adipose tissue. LV impairment was defined as a combined 
endpoint of LGE, EF <55% or LVCI > 1.3 g ml-1” (Rado et al. 2019). This table has been 
previously published in the British Journal of Radiology (Rado et al. 2019). 
  Epicardial fat Paracardial fat 
LV impairment β (95 CI) p-value β (95 CI) p-value 
Unadjusted 1.80 (0.57; 3.03) 0.004 6.9 (3.3; 10.49) <0.001 
Adjusted for     
Age, gender, 
smoking, 
hypertension, 
LDL 
1.26 (0.18; 2.35) 0.02 4.92 (1.79; 8.05) 0.002 
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Age, gender, 
smoking, 
hypertension, 
LDL, diabetes 
1.63 (0.5; 2.76) 0.005 2.63 (-0.75; 6.00) 0.13 
Age, gender, 
smoking, 
hypertension, 
LDL, diabetes, 
BMI 
0.95 (-0.15; 2.05) 0.09 1.63 (-1.63; 4.89) 0.33 
Age, gender, 
smoking, 
hypertension, 
LDL, diabetes, 
VAT 
1.13 (0.22; 2.03) 0.02 0.88 (-1.53; 3.30) 0.47 
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4. Discussion  
 
 In the present analysis, our aim was to investigate MRI-based, manually 
segmented, single-slice pericardial fat depots with a special emphasis on associations 
with impaired glucose metabolism and signs for subclinical left-ventricular impairment 
in a clinically cardiovascular healthy cohort from the general population (Rado et al. 
2019). In summary, the manual assessment of epicardial and pericardial fat in the systolic 
and diastolic heart cycle was feasible when employing the cine SSFP sequence in the long 
axis (four chamber view). Higher inter-reader and intrareader reproducibility was found 
for systolic as compared to diastolic readings (Rado et al. 2019). A strong correlation was 
seen between the volumetric and the single-slice assessment of pericardial fat. Very 
strong correlations were found between systolic and diastolic measurements for all 
pericardial fat depots. In general, systolic measurements were higher than diastolic 
measurements. Men had higher amounts of all fat depots as compared to women and 
regardless of the systolic or diastolic measurements.  
 There were significant differences seen in the amounts of epicardial and 
paracardial fat between prediabetics, diabetics and controls. We found a significant 
increase in epicardial as well as paracardial fat from healthy subjects to prediabetics and 
diabetics (Rado et al. 2019). Upon stepwise adjustment for traditional cardiovascular risk 
factors including body fat depots, this association became non-significant for both 
epicardial and paracardial fat. Multivariate analysis revealed that VAT was the best 
predictor for epicardial as well as paracardial fat (Rado et al. 2019) whereas no significant 
association was found for other traditional cardiovascular risk factors. 
 Subjects with signs for early subclinical LV impairment as determined on MR 
images had significantly higher amounts of epicardial and paracardial fat (Rado et al. 
2019). Epicardial fat was independently associated with MRI-derived signs for early LV 
impairment (endpoint: LVEF<55%; presence of LGE; LVCI >1.3g/ml) after adjusting 
for traditional cardiovascular risk factors including VAT, but a loss of significance was 
seen when adjusting for BMI instead of VAT. There was no independent association 
between paracardial fat and signs for LV impairment (Rado et al. 2019).  
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The manual assessment of the pericardial fat depots on MR images in the cine SSFP 
sequence was feasible (Rado et al. 2019). SSFP sequences are considered standard CMR 
sequences for analysis of especially the LV structure and function and are the preferred 
sequence for cine imaging (Kramer et al. 2013). Among others, SSFP imaging has been 
included in MR imaging protocols in emerging epidemiological studies including the 
German National Cohort (Bamberg et al. 2015) or the UK Biobank (Petersen et al. 2016). 
While labor-intensive and time-consuming, manual segmentation of the pericardial fat 
depots using this sequence has been found practicable in our approach; especially since 
the cine-sequence offers the possibility to assess the fat depots not only in one heart cycle 
but in the systole and the diastole. This finding is important as it allows for segmentation 
of the pericardial fat depots using standard images acquired during a whole-body MRI 
exam without employing an additional, specialized MRI sequence. Segmentation can 
only be conducted upon identification of the thin pericardium; however, identification 
was unsuccessful in only one data set of the 400 subjects included. The epicardial fat 
depot can then easily be detected as the fat located between the myocardium and the 
pericardium. In an attempt to avoid mistakes by overlapping ROIs, we opted to segment 
only the epicardial and the pericardial fat amounts and then deduct the amount of 
epicardial fat, thus obtaining the amount of paracardial fat. Similar approaches of 
segmenting only two of the fat depots and calculating the missing one by subtraction, 
have been described earlier (Thanassoulis et al. 2010a). Additionally, it needs to be 
pointed out that we did not segment small, non-fatty structures embedded in the 
pericardial fat depots separately. Thus, a minimal overestimation of the fat amounts 
cannot be ruled out in our study cohort. This attempt is in contrast to other approaches 
towards the fat assessment. In studies employing CT images for pericardial fat 
assessment, dedicated Hounsfield units were attributed to fat and the fat depots were then 
semi-automatically analyzed (Thanassoulis et al. 2010a). However, since we used our 
approach for all study subjects included in the final analysis, our data set can still be 
regarded as consistent within itself. 
We found that the intraclass correlations were higher for the intrareader than for the 
interreader comparison. Similar results have been reported from the Framingham Heart 
Study (Rosito et al. 2008). This finding is expected and may stem from the routine an 
individual reader develops during the segmentation process. Intrareader as well as 
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interreader results were better for the pericardial as compared to the epicardial fat depots 
in both the systole and diastole. Rosito et al note the same finding of higher intraclass 
correlations for pericardial as compared to epicardial fat segmentation (Rosito et al. 
2008), although they only segmented the fat depots in one heart cycle. This finding may 
be explained by the smaller size of the epicardial fat depot which may more easily result 
in segmentation errors.  Interestingly, when comparing systolic and diastolic 
measurements, intrareader and interreader reproducibility were higher for the systolic 
measurements. This finding may be explained by better delineation and thus higher rates 
of agreement of the fat depots as the heart is contracted (Rado et al. 2019). In 
consideration of this finding, we decided to employ the systolic data in our statistical 
analysis (Rado et al. 2019), unless otherwise indicated.  
 
A good correlation was found between manually assessed single-slice pericardial fat 
and automatically assessed volumetric pericardial fat. Similar results for a planimetric 
versus volumetric approach for the epicardial fat depot as derived from CT images have 
been reported by Oyama et al (Oyama et al. 2011). Additionally, Sironi et al found that 
cardiac fat mass correlated with the cardiac fat area from assessment in the four-chamber 
view in a cohort of N=20 healthy subjects (Sironi et al. 2012). Our finding can be seen as 
reassurance that the selected sequence, approach and segmentation technique are 
acceptable for pericardial fat assessment.  
 
In our study, prediabetics and diabetics had a more unfavorable constellation 
concerning traditional cardiovascular risk factors such as the presence of hypertension or 
elevated triglycerides when compared to subjects with normal glucose tolerance (Rado et 
al. 2019). This finding may be due to impaired glucose metabolism being a part of the 
metabolic syndrome that is known as an array of disturbances in e.g. lipid metabolism 
and blood pressure (Grundy et al. 2004). There was an increase in the fat depots VAT, 
SAT, and PDFFhepatic from normoglycemic subjects to subjects with impaired glucose 
metabolism (Rado et al. 2019). It is well established that the accumulation of VAT is 
associated with an unfavorable cardiometabolic risk profile, even in healthy subjects (De 
Larochellière et al. 2014). In the Framingham Heart Study, Fox et al found VAT to be 
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associated with an adverse metabolic risk in 3001 subjects, independent of BMI or waist 
circumference (Fox et al. 2007). We found subjects with prediabetes and diabetes to be 
taking more cardioprotective medication such as antihypertensive or lipid-lowering 
medication than healthy controls (Rado et al. 2019). This finding needs to be taken into 
consideration when interpreting further results as these pharmaceuticals may influence 
the two investigated structures, namely body fat depots and cardiac function. Thus, our 
study results cannot be directly compared to drug-naïve individuals.  
 
There was a significant increase seen in the composite endpoint of subclinical LV 
impairment (LVEF<55%; LVCI >1.3g/ml; presence of LGE) from subjects with normal 
glucose tolerance to prediabetics and diabetics in this clinically cardiovascular healthy 
cohort (Rado et al. 2019). As has been mentioned earlier, it is known that diabetes is one 
of the major contributors towards cardiovascular disease (Kannel and Mcgee 1979). Our 
results, in conjunction with other findings from the same cohort (Bamberg et al. 2017) 
show that cardiovascular alterations already occur in prediabetic stages, and that these 
subclinical changes can be visualized by MRI. Future applications for these findings 
might open new ventures for preventative medicine.  
A significant increase in LV myocardial mass was noted in subjects with impaired 
glucose metabolism (Rado et al. 2019). This finding may be attributed to early structural 
changes of the myocardium in response to impaired glucose metabolism. An increase in 
LV mass in impaired glucose metabolism has previously been reported especially for 
women in the Framingham Heart Study by Rutter et al (Rutter et al. 2003). It is known 
that impaired glucose metabolism induces structural alterations such as increasing central 
artery stiffness (Schram et al. 2004).  
 
Within the 372 data sets included in the final analysis, the epicardial fat depots 
assessed in both the systole and the diastole were smaller than the paracardial fat depots 
(Rado et al. 2019). An inverse relation has been reported from the Framingham Heart 
Study by Mahabadi et al (Mahabadi et al. 2009). Sicari et al measured epicardial and 
paracardial fat on both echocardiography (thickness) and MR images (area) in the same 
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cohort and found the epicardial fat depots to be smaller than paracardial fat, regardless of 
the imaging method applied (Sicari et al. 2011). We conclude that both fat depots are 
volatile in size within the general population and contribute with our results to the broader 
picture.  
We found a median of 8.7 cm2 for epicardial fat and 18.3 cm2 for paracardial fat for 
all subjects (Rado et al. 2019) in the systolic assessment and 7.7 cm2 and 16 cm2 in the 
diastolic assessment, respectively. While every individual had measurable paracardial fat, 
the absence of measurable epicardial fat was noted in a few cases. We did not multiply 
the amount of fat with the slice thickness but worked with the primary numbers to avoid 
calculative bias. In a study conducted in Italy, MRI data derived from diastolic 
measurements showed a mean epicardial fat area of 8.27 cm2 and mean paracardial fat 
area of 18.13 cm2 (Sicari et al. 2011). Similar amounts have been reported by others 
(Sironi et al. 2012) and these data reflect our findings very well. We found that our results 
of epicardial fat are higher than for example by Oyama et al (Oyama et al. 2011) who 
measured epicardial fat areas in CT on certain anatomical levels in Japan. It is known that 
epicardial fat is ethnicity-dependent and therefore cannot be directly compared (Salami 
et al. 2013, Adams et al. 2017).  
In general, men had higher median amounts of all fat depots than women, regardless 
of the systolic or diastolic measurements. Gender differences in epicardial fat have been 
described previously, e.g. by Dagvasumberel et al, who found higher epicardial fat 
volume in men as compared to women but differences became comparable when 
adjusting for height and body surface index (Dagvasumberel et al. 2012). De 
Larochiellère et al also found higher amounts of epicardial fat in men than in women (De 
Larochellière et al. 2014). However, it needs to be noted that our results are purely 
descriptive and have not been adjusted for height, weight or body surface area. 
 
There was a strong correlation seen between data-sets derived from segmentations 
conducted in the maximal systole and the maximal diastole. Single-slice segmentation of 
pericardial fat depots in MRI in the long axis has been conducted in a couple of studies 
(Sironi et al. 2012, Sicari et al. 2011, Jonker et al. 2013, Van Schinkel et al. 2014) but to 
our knowledge, there are no cohort study data on the comparability of the diastolic and 
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systolic measurements in this view so far. Teme et al showed strong correlations between 
epicardial fat assessment in the end-systole and end-diastole on short-axis MR images in 
20 subjects (Teme et al. 2014) and we support the same finding for the cardiac long-axis 
four chamber view in a cohort comprising 372 individuals. The highest correlation 
coefficient was seen for pericardial fat, followed by paracardial fat and then epicardial 
fat. We hypothesize that this finding relates to the absolute sizes of the fat depots. The 
strong correlations between both data sets also support the use of one dataset only for 
more sophisticated statistical analyses. It needs to be considered that the maximal systole 
and maximal diastole were determined subjectively on each image, which may 
theoretically constitute a source of error.  
 
Data derived from the systolic measurements were generally larger for all fat depots 
as compared to measurements in the diastole. This finding may be explained by 
employing a single-slice measurement and the contraction of the heart during the systole 
drawing surrounding structures including the fat depots into the field of view. Similar 
observations have been made for echocardiographically derived epicardial fat thickness 
in systole and diastole (Graeff et al. 2016). As the epicardial fat depot is anatomically 
closer to the movements of the heart than the paracardial fat depot, differences between 
systole and diastole were slightly larger for the epicardial fat depot than for paracardial 
fat.  
 
We found a significant increase in both the epicardial and paracardial fat depots from 
subjects with normal glucose tolerance to prediabetics and diabetics (Rado et al. 2019).  
Previous research found, that epicardial fat is increased in diabetes (Song et al. 2015) and 
even prediabetes (Arpaci et al. 2015). Moreover, epicardial fat thickness has been shown 
to be associated with diabetes prevalence in a male Korean cohort independent of multiple 
cardiovascular risk factors (Chun et al. 2015). Iacobellis and Leonetti stated, that there is 
a relation between epicardial fat and insulin-resistance (Iacobellis and Leonetti 2005). 
Thereby, our results are in line with the current literature and indicate that there may be 
structural changes in the body fat composition in impaired glucose metabolism and 
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insulin-resistance and the amount of epicardial fat seems to be associated with metabolic 
alterations.  
However, there is not much literature on the increase of paracardial fat in the light of 
impaired glucose metabolism. Thanassoulis et al argued that paracardial fat is correlated 
with metabolic risk in a study comprising 3,312 participants (Thanassoulis et al. 2010a) 
and Sicari et al also found correlations between paracardial fat and signs for metabolic 
syndrome in a study cohort of 49 subjects (Sicari et al. 2011). 
Data trends are very similar for assessment in the maximal diastole in the same study 
population. They also show a significant stepwise increase from healthy subjects to 
prediabetics and diabetics for both fat depots. However, and as discussed earlier, the 
absolute numbers are slightly smaller. 
 
Upon adjustment for age and gender, the association between prediabetes and 
epicardial fat attenuated. Furthermore, in subjects with diabetes, a loss of significance 
was found after adjusting for age, gender and traditional cardiovascular risk factors, 
whereas the association of paracardial fat and diabetes remained significant after 
adjusting for age, gender, traditional cardiovascular risk factors, BMI and SAT. The 
association between paracardial fat and diabetes became only non-significant after the 
additional adjustment for VAT (Rado et al. 2019). The differences in the loss of 
significance between the prediabetes and diabetes group may be explained by the more 
advanced structural changes in diabetes as compared to prediabetes in the development 
of the disease. Interestingly, traditional cardiovascular risk factors can be depicted as 
confounders for the association between diabetes and epicardial fat in our study. High 
levels of interaction between different cardiovascular risk factors are known; it has, for 
example, been shown that epicardial fat is associated to smoking (Monti et al. 2014) and 
the metabolic syndrome (Wang et al. 2009). On the other hand, epicardial fat, smoking, 
diabetes, or age influence coronary artery disease (Jeong et al. 2007). In short, our results 
contradict previously conducted studies such as Wang et al who found independent 
associations between CT-measured epicardial fat and diabetic status (Wang et al. 2009).  
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Available data in the literature are scarce for paracardial fat. Interestingly, we detected 
an association of paracardial fat to diabetes even after adjusting for age, gender and 
traditional risk factors (Rado et al. 2019). This finding is interesting by showing that the 
fat depot distant to the myocardium is not primarily affected by typical cardiovascular 
risk factors. As has been described earlier, Sicari et al found that paracardial fat correlates 
better with cardiometabolic risk markers than epicardial fat (Sicari et al. 2011). However, 
all associations became non-significant after additional adjustment for VAT, thereby 
underlining the potency and uniqueness of this distinct fat depot as previously described 
in the Framingham Heart Study (Fox et al. 2007). We conclude from our data that there 
is no independent association between either epicardial or paracardial fat and impaired 
glucose metabolism (Rado et al. 2019). Nonetheless, our study analyzes the contributions 
of epicardial and paracardial fat towards impaired glucose metabolism and in the context 
of other cardiovascular risk factors in this stepwise approach in great detail. 
 
In multivariate analysis, the strongest predictor for both epicardial and paracardial fat 
was VAT (Rado et al. 2019). Our results of this analysis are in line with other groups who 
reported a significant correlation particularly for epicardial fat and VAT (Iacobellis et al. 
2003), and a correlation especially in obese diabetics (Jain et al. 2015). VAT has been 
discussed as one of the ectopic fat storage sites to be used when other fat storage sites 
cannot compensate anymore (Smith 2015). Our study underlines the importance of VAT 
in the development of cardiometabolic disease states due to its detrimental effects via 
epicardial adipose tissue. Earlier studies have even suggested epicardial fat as a measure 
for VAT (Iacobellis et al. 2003). Interestingly, Graeff et al analyzed epicardial fat 
thickness by echocardiography in the ELSA-Brasil study and found that associations to 
cardiometabolic variables were mostly influenced by age, gender, race and central 
adiposity which was measured as waist circumference in this particular study (Graeff et 
al. 2016).  
A weaker association was found between epicardial fat and current smoking. As has 
been described, an association between epicardial fat and smoking has been discussed 
earlier in subjects with metabolic syndrome (Monti et al. 2014) and our study certainly 
comprises subjects with that complex metabolic manifestation. 
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It is known that paracardial fat correlates with VAT, as has been shown in the 
Framingham Heart Study by Thanassoulis et al (Thanassoulis et al. 2010a) and we are in 
line with that finding. Moreover, Sironi et al stated that it may be paracardial fat that is 
more associated with cardiovascular risk (Sironi et al. 2012), thus making it unclear to 
which extent which pericardial fat depot contributes to cardiovascular disease. 
Paracardial fat has been described to show an indifferent behavior between subcutaneous 
and epicardial fat as shown in the context of weight loss by Foppa et al (Foppa et al. 
2013).  
 
As our original cohort only comprises subjects without clinically manifest 
cardiovascular disease, we defined imaging-based parameters that represent subclinical 
pathological LV changes. The presence of LGE is a marker for focal fibrosis, for example 
after myocardial ischemia (Wu et al. 2001). LVCI is a marker for cardiac remodeling 
(Pun et al. 2011). An LVEF <55% has been suggested as a cutoff for patients with heart 
failure with preserved ejection fraction who may progress to reduced ejection fraction 
(Ueda et al. 2015). Interestingly, when combining these markers of LV impairment, both 
the epicardial and paracardial fat depots were higher in subjects fulfilling the criteria for 
this composite endpoint (Rado et al. 2019). Epicardial fat has been shown to affect the 
coronary microvasculature (Gaborit et al. 2012) and our findings also hint at a 
pathological influence of epicardial fat in the very early stages of LV impairment. Again, 
our study underlines the potential of imaging-based prevention in the future as very early 
LV changes can be detected before a clinical manifestation occurs.  
When stepwise adjusted, the association between epicardial fat and the composite 
endpoint of LV impairment remained significant after adjustment for diabetes and other 
cardiovascular risk factors. Even upon additional adjustment for VAT, the association 
remained independent. However, when adjusted for BMI instead of VAT, the association 
was rendered non-significant (Rado et al. 2019). We currently do not have a sufficient 
explanation for this finding although our hypothesis is that the different fat depots that 
are summarized in the calculated BMI may play different roles in the human body (Rado 
et al. 2019). As described earlier, the epicardial fat depot is very close to the myocardium 
and the coronary vessels and they are not separated by a fascia (Corradi et al. 2004). Our 
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finding may emphasize the strong local effect that epicardial fat has on its surrounding 
structures, even in clinically cardiovascular healthy subjects (Rado et al. 2019). 
Interestingly, the association between paracardial fat and LV impairment was 
rendered non-significant after adjusting for traditional cardiovascular risk factors 
including diabetes status (Rado et al. 2019). This finding may be explained by the 
anatomical remoteness of the paracardial fat depot to the myocardium and the coronary 
vessels. 
 
Future Directions for the use of epicardial fat data as derived from MRI are promising. 
Firstly, due to its non-ionizing nature, MRI is a unique tool for screening clinically 
healthy subjects. Nowadays, the SSFP sequence is a standard sequence in most CMR 
protocols (Kramer et al. 2013), thereby not prolonging the measurement process or 
delaying the routine work-flow. The segmentation of the pericardial fat depots can easily 
be integrated into the reporting routine. Nevertheless, concerns about the financial aspects 
and length of performing CMR have been raised (Madonna et al. 2019). MRI-based 
screening for epicardial fat as a predictor for dysfunctional adiposity can, in the future, 
hopefully be offered to subjects with symptoms of the metabolic syndrome who are at 
risk for developing adverse cardiac events in the future. Also, subclinical LV impairment 
can be analyzed on these MR images before it becomes clinically manifest. Hopefully 
epi- and paracardial fat can be used as predictors for the overall fat status of an individual 
as well. BMI and waist circumference measurements could then be underpinned by more 
sophisticated fat analysis without subjects undergoing time-consuming whole-body 
MRIs. The planimetric assessment of cardiac fat could also be integrated in the workflow 
when performing necessary non-contrast calcium-scoring CTs. The assessment of epi- 
and paracardial fat should be seen as an integral part in analyzing the complete body 
structure and the creation of imaging-based panels related to clinical and laboratory 
measurements should be aspired. This could help determine the subject’s overall 
metabolic status and improve the individual risk assessment. Additionally, these data 
could – with the individual’s informed consent – then be applied to develop a plan for 
individualized prevention, diagnostics and therapies but also to calculate estimated 
healthcare costs not only or the individual but for the general population. Data can also 
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be used to compare them to a larger set of anthropometric measurements and other fat 
compartments in the human body, such as renal/retroperitoneal fat in order to fully 
understand the fat deposition in the human body.  
The paracardial fat depot is widely unexamined and may very well not directly play 
a role in the development of cardiovascular disease but interact with the other different 
fat depots of the human body. Therefore, further research into this particular fat depot 
should be of high interest.  
 
Our study has limitations. Firstly, our cohort consists of Caucasian Western-European 
subjects only, therefore results concerning the amount of pericardial fat compartments of 
our study are only partially applicable to other, ethnically more diverse populations as 
has been discussed previously (Rado et al. 2019) and shown in several studies conducted 
so far (Adams et al. 2017, Apfaltrer et al. 2014). Moreover, subjects in the three subgroups 
‘normal glucose tolerance’, ‘prediabetes’ and ‘diabetes’ were not matched for e.g. age, 
gender or BMI and differed additionally in sample size. Thus, a part of our data has only 
descriptive character. We tried to overcome that fact by multivariate analysis but noted, 
that further prospective studies including matched and randomized subjects would be 
preferable (Rado et al. 2019). Also, subjects with prior cardiovascular disease were 
excluded from the study, thereby leaving the study cohort with clinically cardiovascular 
healthy subjects. In order to still analyze the effect of the fat depots on the left ventricle 
we had to employ imaging-based variables that helped us understand the subclinical 
implications of especially epicardial fat. Moreover, we could not analyze clinically 
manifest cardiac diseases and outcomes (Rado et al. 2019). While the previous facts may 
be seen as a limitation, it needs to be noted though, that this study is a baseline study and 
outcomes are not yet available. Thus, a longitudinal approach would be preferable in 
order to examine whether our findings with subclinical variables are of clinical 
significance in the future. Additionally, further studies including greater numbers of 
subjects with and without prior cardiovascular disease are warranted. Subjects included 
in the study were mostly not newly diagnosed with diabetes or under antidiabetic therapy 
according to German guidelines. This fact, together with the intake of cardioprotective 
medication in many study subjects, may have influenced our findings and may be 
69 
responsible for the early loss of significance concerning established cardiovascular risk 
factors. Also, we only included subjects with type 2 diabetes into the study. We 
segmented the pericardial fat depots manually. Also, maximal systole and diastole as well 
as the pericardium were subjectively identified, which may theoretically present a 
subjective source of error (Rado et al. 2019). Hence, a consensus reading was conducted 
to rule out possible great errors. Our study also shows a good correlation between 
manually and automatically assessed pericardial fat and we may hopefully overcome the 
problem of manual segmentation soon. 
 
In conclusion, the manual assessment of the pericardial fat compartments on MR 
images in the cine SSFP-sequence in the long axis (four chamber view) is feasible with 
the chosen approach (Rado et al. 2019). There were strong correlations seen between data 
derived from the systole and the diastole while measurements from the systole were 
larger. Our manually derived data for pericardial fat from single-slice long-axis 
measurements correlated well with automatically derived, volumetric data for pericardial 
fat.  
In all subjects included, the median paracardial fat depot was larger than the epicardial 
fat depot (Rado et al. 2019) and men had more median paracardial and epicardial fat than 
women. There were significant differences in epicardial as well as paracardial fat between 
healthy subjects, prediabetics and diabetics in our cohort without clinical manifest 
cardiovascular disease. However, the association between epicardial and paracardial fat 
to impaired glucose metabolism was not independent of other traditional cardiovascular 
risk factors. VAT was the strongest predictor for epicardial as well as paracardial fat in 
multivariate analysis (Rado et al. 2019). We also found an increase in subclinical 
measures of LV impairment ranging from healthy subjects to prediabetics and diabetics. 
Subjects with the composite endpoint of LV impairment had significantly higher amounts 
of both epicardial and paracardial fat. Upon stepwise adjustment, epicardial fat was 
independently associated with the composite endpoint of LV impairment, even when 
additionally adjusting for VAT but not for BMI. However, no independent association 
between paracardial fat and signs of subclinical LV impairment was found (Rado et al. 
2019).  
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Our study contributes to a better scientific understanding of both the epicardial and 
paracardial fat depot. We underline the feasibility of manually analyzing the cardiac fat 
depots on a standard MRI sequence which opens new venues for image interpretation in 
the diagnostic routine. While there is no independent association between impaired 
glucose metabolism and epicardial or paracardial fat, our study emphasizes the 
importance of VAT in the development of cardiometabolic diseases and the local 
deteriorating effect that epicardial fat has on the myocardium independent of VAT. 
Finally, our study results indicate, that an increase of epicardial fat seems to be one of 
many factors within the complex pathomechanism of cardiovascular and metabolic 
alterations, even in subclinical diseases. 
  
71 
Abstract 
 
Objective: To manually assess the pericardial fat depots on MRI (Magnetic Resonance 
Imaging) in a clinically cardiovascular healthy cohort and investigate associations 
between epicardial/paracardial fat and disturbances in the glucose metabolism as well as 
measures for subclinical left ventricular (LV) impairment. 
Material and Methods: 400 subjects from the KORA FF4 cohort with established 
glucose tolerance status underwent whole-body 3 Tesla MRI exams. Segmentation of the 
pericardial fat depots in the systolic and diastolic heart cycle was performed manually 
using a cine steady-state free precession (SSFP) sequence in the four-chamber view. Late 
gadolinium enhancement, LV concentricity index > 1.3g/ml and LV ejection fraction 
<55% were used to define LV impairment.  
Results: A total of 372 subjects were included in the final analysis. Systolic and diastolic 
measurements correlated very well (all r≥0.90). Epicardial and paracardial fat showed an 
increase from healthy subjects to prediabetics and diabetics (all p<0.001). The association 
between epicardial fat and diabetes became non-significant after adjusting for age, 
gender, hypertension, smoking, low-density lipoprotein (LDL) and triglycerides while 
paracardial fat remained significantly associated with diabetes even after additional 
adjustment for BMI and subcutaneous adipose tissue but not visceral adipose tissue 
(VAT). In multivariate analysis, VAT was the strongest predictor for epicardial and 
paracardial fat (both p<0.001). Epicardial fat was associated with subclinical measures of 
LV impairment independent of age, gender, smoking, diabetes status, hypertension, LDL 
and VAT (p=0.02) but not BMI (p=0.09). 
Conclusion: Increased epicardial and paracardial fat seen in prediabetics and diabetics is 
not independent of other cardiovascular risk factors including VAT. Epicardial but not 
paracardial fat is associated with early signs for LV impairment.   
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Zusammenfassung 
 
Ziel: Ziel der Arbeit war die manuelle Quantifizierung der perikardialen Fettdepots 
mittels MRT (Magentresonanztomographie) in einer klinisch kardiovaskulär gesunden 
Kohorte sowie die Bestimmung der Assoziation zwischen epikardialem/parakardialem 
Fett und gestörtem Glukosestoffwechsel sowie Zeichen subklinischer linksventrikulärer 
(LV) Einschränkung. 
Material und Methoden: 400 Probanden aus der KORA FF4 Kohorte mit etabliertem 
Glukosetoleranzstatus wurden mittels 3 Tesla Ganzkörper MRT untersucht. Die 
Segmentierung der perikardialen Fettdepots im systolischen und diastolischen 
Herzzyklus erfolgte manuell unter Benutzung einer cine steady-state free precession 
(SSFP) Sequenz im Vierkammerblick. Late Gadolinium Enhancement, LV 
Konzentrizitätsindex >1.3g/ml und eine LV Ejektionsfraktion <55% wurden zur 
Definition der LV Einschränkung verwendet.  
Ergebnisse: Es wurden 372 Probanden in die Analyse eingeschlossen. Systolische und 
diastolische Messungen korrelierten sehr gut (alle r≥0.90). Epikardiales und parakardiales 
Fett zeigten einen Anstieg von gesunden Probanden zu Prädiabetikern und Diabetikern 
(alle p<0.001). Die Assoziation zwischen epikardialem Fett und Diabetes wurde nicht 
signifikant nach Adjustierung für Alter, Geschlecht, Bluthochdruck, Rauchen, low-
density lipoprotein (LDL) und Triglyceride. Parakardiales Fett blieb signifikant mit 
Diabetes auch nach zusätzlicher Adjustierung für BMI und subkutanes Fettgewebe aber 
nicht viszerales Fettgewebe (VAT) assoziiert. In der multivariaten Analyse war VAT der 
stärkste Prädiktor für epikardiales und parakardiales Fett (beide p<0.001). Epikardiales 
Fett war mit subklinischen Markern einer LV Schädigung unabhängig von Alter, 
Geschlecht, Rauchen, diabetischem Status, Bluthochdruck, LDL und VAT (p=0.02), aber 
nicht BMI (p=0.09) assoziiert. 
Fazit: Erhöhtes epikardiales und parakardiales Fett bei Prädiabetikern und Diabetikern 
ist nicht unabhängig von anderen kardiovaskulären Risikofaktoren inklusive VAT. 
Epikardiales aber nicht parakardiales Fett ist mit frühen Zeichen einer LV Einschränkung 
assoziiert.  
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